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The filarial parasite, Dirofilaria immitis, infects dogs and canids in warm and tropical 
areas of the globe. Located in the right pulmonary arteries, the heartworm infection is 
a severe and potentially fatal disease; caused mainly by the adult worm stages. The 
zoonotic roundworm is transmitted by various mosquitoes, Culicidae.  
Currently, control measures are based on monthly prophylaxis with macrocyclic 
lactones (MLs). The only adulticide treatment is melarsomine dihydrochloride injected 
intramuscularly which can cause complications. Resistance is emerging against the 
MLs, increasing the necessity to find novel anthelmintics.  
The recently discovered class of anthelmintics, amino acetonitriles derivatives 
(AADs), with a new mode of action brought hope in the battle against helminth 
parasites. The aim of this thesis was to find candidate targets of AADs and other 
potential anthelmintics in D. immitis genome that could be used as therapeutic 
targets.  
The first chapter discusses the possible mechanisms of antiparasitic drug action and 
selectivity.  
The second chapter tests and confirms the efficacy of AADs against D. immitis in 
vitro. This suggests the presence of receptor(s) to AADs in the heartworm, a 
hypothesis which can be tested by genome sequencing. 
The third chapter narrates the story of the genome project of the heartworm; de novo 
sequenced with Illumina HiSeq and assembled with Abyss and Velvet. This did not 
indicate that there is an AAD receptor (DEG-3-subfamily), to Caenorhabditis elegans 
and Haemonchus contortus in D. immitis genome. In fact, D. immitis does not appear 
to possess a single gene of the DEG-3 subfamily of acetylcholine receptors, the 
targets of monepantel. However, in-depth studies of the genome through exclusion 
criteria established a list of novel potential drug targets. 
The fourth chapter further investigates the presumed loss of the DEG-3-subfamily in 
D. immitis and relates this finding to the sensitivity against both monepantel 
enantiomers in vitro and in vivo. 
The fifth chapter picks up some of the newly identified candidate drug targets. It tests 
the predicted targets against the heartworm with known inhibitors. 
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This thesis presents a genomic approach to identify potential targets and new 
anthelmintics. I hope that, the genomic approach will support the development of 
drugs against the heartworm and related parasites.  
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Dirofilaria immitis 
Phylogeny and morphology 
Nematodes are Ecdysozoans (as are Arthropods). This grouping is supported by 
morphological characters and includes all animals that shed their exoskeleton. Their 
major characteristic is the three-layered cuticle composed of organic material, which 
is periodically molted as the animal grows. This process is typically known as 
ecdysis. Furthermore, the nematodes are characterized by a complete open digestive 
system with mouth, intestine and anus (1). 
The order Spirurida is characterized by ventral and caudoventral papillae and 
possesses an esophagus divided into muscular and posterior glandular parts. The 
nematodes of this order have intermediate hosts as part of their lifecycle. The 
superfamily Filarioidea, representing the filarial nematodes, is defined by 
intermediate hosts that are biting flies such as mosquitoes, blackflies or others. The 
infection of the definitive host occurs by inoculation of L3 from these flies while 
feeding (2). 
Filarial nematodes are members of the order Spirurida and can be assigned to a 
single family, the Onchocercidae, divided into two subfamilies, the Dirofilarinae and 
the Onchocercinae. The genus Dirofilaria is divided in two subgenera, Nochtiella and 
Dirofilaria. In the Nochtiella subgenus, most species are tissue-dwelling while in the 
Dirofilaria subgenus; Dirofilaria immitis and other species inhabit heart cavities, 
subcutaneous tissues and abdominal cavities (3; 4). 
Nematodes of the genus Dirofilaria are elongated and thin with round anterior 
extremity and rudimentary buccal capsule without lips and small cephalic papillae 
(Figure 1). The esophagus is differentiated into muscular and glandular regions with 
no distinction between them. The caudal extremity of the female is round and the 
vulva aperture is located just behind the union of esophagus and intestine while the 
caudal extremity of the male is rolled in a spiral and more conical. Caudal alae are 
present as well as two spicules of different lengths. Generally, D. immitis nematodes 
are long without striation on the cuticle and the female caudal papillae are slightly 
asymmetrical while the male greater spicule is not clearly pointed. The other species 
of Dirofilaria are smaller with striation on the cuticle and asymmetrical caudal alae, 
while the male greater spicule is clearly pointed (5). 
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Figure 1. Third stage larvae of D. immitis. SEM picture showing the worm cuticle details.1  
 
Figure 2 represents the phylogeny of nematodes based on 18S ribosomal RNA 
studies. It clearly shows the close relation between D. immitis and the Onchocerca 
genus (6; 7). The genus Dirofilaria is cosmopolitan in distribution; the species D. 
immitis is probably the most widespread species because of its association with 
domestic animals (8).  
                                                          
1
 C. Perret (Godel) Master Thesis (2008) 
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Figure 2. Phylogeny of nematodes based on 18S ribosomal RNA (1).2 
 
Repartition and ecology 
Dirofilaria immitis is commonly known as the heartworm. It is found in over 30 
mammalian species including foxes, cats, wolves, coyotes and other wild carnivores, 
but mainly in dogs (9). Dogs are the definitive host and serve as the main reservoir of 
infection, with the heaviest worm burden. The parasite is named heartworm due to 
the location of the adults in the arteries of the lungs and occasionally in the right 
ventricle of the heart. Very common in numerous warm countries and particularly in 
tropical areas, it is widespread throughout the Far West, Equatorial Africa and in the 
Pacific and also occurs in North (Figure 3) and South America, Australia and North 
Africa (8), and South and East Europe (Figure 4).  
                                                          
2
 Blaxter et al. (1998) A molecular evolutionary framework for the phylum Nematoda Nature 392; 71-75 
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Figure 3. US prevalence of antigen positive tests to D. immitis in dogs per county. Counties 
in grey did not reported results. In white, no dog reported as positive (0%). Remaining 
counties were coded as follows: 0.1–2.0% (taupe), 2.1–4.0% (salmon), 4.1–6.0% (red), 6.1–
20.0% (brick red).3 
 
 
Figure 4. Distribution of D. immitis in Europe.4 
 
                                                          
3
 Bowman D. et al. (2009) Prevalence and geographic distribution of Dirofilaria immitis, Borrelia 
burgdorferi, Ehrlichia canis, and Anaplasma phagocytophilum in dogs in the United States: Results of 
a national clinic-based serologic survey Veterinary Parasitology 160; 138-148 
4
 European map of Dirofilaria immitis and D. repens distribution, 
http://www.evsrl.it/vet.journal/archivio_immagini_grandi/2009/3532.jpg 
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The heartworm infection is spreading into areas previously considered free of 
disease and the transmission is also active in heavily urbanized areas. The disease 
is spread by the vector, the mosquito (Culicidae). 
In the last decades, the prevalence of the heartworm increased among dogs and cats 
across the US and Europe (Figures 3 and 4). Recognizing the importance of the 
disease, the American Heartworm Society was established in 1974 (10). The society 
addresses various scientific aspects associated with this potentially fatal disease of 
dogs, which persists even as diagnostic methods advance, preventive therapies 
improve, and disease awareness increases among veterinary professionals and pet 
owners. Another task of the society is to establish protocols and guidelines for 
diagnosis, treatment and prevention in dogs and cats (10). The spread of the disease 
through North America is mainly due to a movement to the North, along rivers and 
streams, of dogs and mosquitoes. The factors favoring the spread of the parasite are 
related to the behavior of vectors and reservoir hosts and to human activities, travel 
of infected dogs. The prevalence rises also due to the urbanization of the wildlife-
parasite relationship resulting in a higher prevalence in the urban zones (11). 
However, the main factor is the temperature. It influences the mosquito abundance in 
the environment and expands the mosquito activity season (12; 13).  
The overall prevalence of the feline heartworm disease is low. Infection with 
immature adults results in heartworm associated respiratory disease (HARD). 
Usually, no clinical signs are observed. Cats infected experimentally showed lesions 
in the lungs as a consequence of the arterial disease and the intense interstitial 
pneumonia. In dogs, radiographs are used as a tool to assess infections with adult D. 
immitis. In cats, the severity of the lung disease cannot be evaluated by lung 
radiography. Moreover, the dog heartworm prevalence cannot be used to estimate 
the prevalence in cats (14). Feline show a native resistance to D. immitis and are less 
attractive to mosquitoes than dogs (15). 
Life cycle 
The infection of the dog occurs when an infected mosquito takes a blood meal and 
infective larvae are deposited on the skin of the dog in a drop of the haemolymph 
(Figure 5). L3 enter the animal’s body via the puncture wound made by the mosquito 
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and migrate through the subcutaneous tissues and thereafter through the muscular 
tissues. 
 
Figure 5.  D. immitis life cycle.5  
 
Presumably larvae are oriented towards the upper abdomen and thoracic cavity, 
traveling between muscle fibers and molting (16). Some 45 to 60 days after infection, 
a second molt occurs and fifth-stage larvae (immature adults) enter the bloodstream 
and migrate to the heart, where they lodge in the arteries of the lungs. Young adults 
continue to grow, become sexually mature around 120 days post-infection and mate. 
When juvenile heartworms first reach the heart and lungs, the pressure of venous 
blood forces them into the small pulmonary arteries. As they grow and increase in 
size, they progressively migrate upstream into larger arteries until the worms become 
fully mature. The eventual location of the mature adult worms appears to depend 
mainly on the size of the dog and the worm burden. Approximately 190 to 197 days 
after infection, microfilariae appear in the circulating blood (17). The lifetime of adult 
heartworms in dogs is about 5 years. The period between the initial infection when 
                                                          
5
 R.B. Grieve, “Epidemiology of canine heartworm infection”, 1983. 
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the dog is bitten by a mosquito and the maturation of worms into adults living in the 
heart takes 6 to 7 months, the prepatent period, before females begin producing 
microfilariae (18). Microfilariae are unsheathed and circulate in the vascular system. 
Their concentration in blood varies over a 24-hour period and seasonally. 
Microfilariae have been shown to develop to the infective stage in a great variety of 
mosquitoes of the genera Aedes, Anopheles, Culex and Mansonia (19; 20; 21). The 
pathophysiological response in the dog is mainly due to the presence of adults in 
pulmonary arteries, provoking a pulmonary hypertension that can progress to 
congestive heart failure. Microfilariae play a minor pathologic role, while larvae or 
adults can disturb the blood flow. The spectrum of pathologies related to chronic 
heartworm infection is broad.  
Diagnosis, treatment and resistance 
Diagnosis of dirofilariosis is mainly done by detecting the circulating microfilariae with 
a blood test or the adults with an antigen test (16). The ultimate goal in any 
heartworm treatment is the elimination of all adult heartworm with minimal post-
treatment complications. To accomplish this aim a thorough understanding of the 
host-parasite interaction is necessary. A combination of doxycycline (10 mg/kg for 30 
days) and ivermectin (6 µg/kg/15 days for 6 months), or another macrocyclic lactone, 
may be a valid alternative, for adulticide therapy in D. immitis naturally infected dogs 
(22).  
The only adulticide available on the market is melarsomine dihydrochloride 
(Immiticide®). It is given through intramuscular injection into lumbar muscles. The 
complications with adulticide include thrombosis and clogging of pulmonary arteries 
due to dead worms (23). Currently, no adulticide treatment exists for cats. Figure 6 
illustrates the timeline of D. immitis development, age of infection in relation to the 
susceptibility of treatment. The susceptibility gap can be eliminated by administering 
a macrocyclic lactone preventive for two to three months prior to administering 
melarsomine. The larvae less than two months old will be eliminated while the older 
larvae will have reached an age at which they will be susceptible to melarsomine (9). 
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Figure 6.  Susceptible and non-susceptible ages of heartworm to macrocyclic lactones and 
melarsomine based upon the age of the worm in days.6  
 
Current knowledge about MLs as heartworm preventives were summarized by 
McCall (24). Many preventives are currently available against heartworm lifestages 
(not against adults), and ivermectin has the highest safety-net (efficacy duration and 
rate) but a miserable adulticidal activity (approximately only 20%), reducing the risk 
for the dog.  
MLs, preventives are highly effective against the majority of D. immitis isolates. 
However, a lack of effectiveness of macrolide heartworm chemoprophylactic agents 
was described recently and appears to have a genetic basis (25). A successful 
prophylaxis requires drugs to be administered at the appropriate dose and time for 
the duration of the period of exposure to infection. For an appropriate treatment it is 
recommended to test dogs annually. The growing lack of efficacy of MLs’ is mainly 
due to failure in prophylactic administration. To reduce the infection rate, it is 
important to maintain annual heartworm tests and to reduce the time dogs spend 
outdoors (26). 
Early 2011, Bourguinat et al. (27) described for the first time a resistant case of 
heartworm to MLs. A naturally infested dog remained positive in microfilarial tests 
despite repeated treatments with high doses of MLs. The authors highlighted the 
                                                          
6
 http://www.heartwormsociety.org/veterinary-resources/canine-guidelines.html 
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presence of two single nucleotide polymorphisms in the P-glycoprotein gene which 
correlate with a reduction of the sensitivity to MLs.  
To overcome resistance to the main chemical classes utilized against the heartworm, 
a new preventive chemical class, with a new mode of action, would be most helpful. 
In the discovery of a new class of anthelmintics, the amino-acetonitrile derivative 
(AAD) is very important (28). AADs are active against various species of gastro-
intestinal nematodes, have a low toxicity to mammals, and have favourable 
pharmacokinetic properties. AAD anthelmintic action requires a unique subtype of 
nicotinic acetylcholine receptor (nAChR) which is specific to nematodes. In C. 
elegans this receptor is acr-23, and loss of function mutations in ACR-23 cause AAD 
resistance (28). In Haemonchus contortus, AAD sensitivity is mediated by the 
receptors MPTL-1 and DES-2. All these proteins (ACR-23, MPTL-1, and DES-2) 
belong to the DEG-3 group that is a nematode specific subfamily of nAChR. AADs 
are allosteric activators of these receptor channels (29).  
Dirofilaria genomics raises hopes for a better understanding of the parasite, the 
disease, its prevention and treatment (30). Sequencing of 4005 expressed sequence 
tags (ESTs) of D. immitis adults identified about 1800 genes (31). 70% of these 
identified D. immitis genes showed significant similarity to a B. malayi gene. 
However, there was no DEG-3 type nAChR gene among the D. immitis ESTs, while 
B. malayi possesses two such genes (32; 33). ESTs sequencing only identifies 
expressed genes. So ultimately, the question whether D. immitis possess DEG-3 
type nAChR genes can only be resolved by whole genome sequencing.  
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Old and new sequencing strategies 
 
DNA sequencing 
DNA sequencing refers to various methods to determine the nucleotide sequence of 
a DNA molecule. DNA sequencing is useful in different ways such as diagnosis, 
biotechnology, forensic biology, systematics, evolution and identification of drug and 
vaccine targets (35). The increase in sequencing speed with novel methods has 
been accelerating biological research and discoveries.  
At the end of the 1970s the first biological sequencing methods were developed (36-
40). In 1980, Sanger F., Gilbert W. and Berg P. were awarded with the Nobel Prize in 
Chemistry for their brilliant inventions in the DNA-sequencing area (41). Dideoxy 
sequencing in particular allowed the determination of the complete DNA sequence of 
thousands of genes and over 250 genomes (42). 
Premises - Sanger, Maxam and Gilbert 
In 1977, Maxam and Gilbert (39) developed another sequencing method based on 
chemical modification of DNA followed by subsequent cleavage at specific bases. In 
the Maxam-Gilbert technology, DNA fragments to be sequenced need to be purified 
and are radioactively labeled at one end. Chemical treatment generates breaks at a 
small proportion of one or two of the four nucleotide bases in each of the four 
reactions, G, A+G, C, and C+T. This ends in a series of labeled fragment of different 
length that are arranged side by side in an electrophoresis gel and they are 
separated by size. The sequence is reconstructed after exposing the gel to X-ray film 
(39). 
 
The Sanger sequencing is based on the incorporation of dideoxyribonucleotides 
(Figure 7) (34; 37). Dideoxyribonucleotides do not have a 3’ hydroxyl being 
chemically synthesized DNA template strand, DNA polymerase, short primers (to 
initiate the synthesis of DNA by DNA polymerase), one of the four tri-phosphate 
dideoxyribonucleotides, ddATP, ddGTP, ddCTP or ddTTP. If a dideoxyribonucleotide 
is incorporated in the growing DNA chain, due to the lack of 3’ hydroxyl group the 
addition of the following nucleotide is blocked and the DNA chain is terminated. This 
template produces a mix of DNA of different lengths, complementary to the DNA 
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sequenced and terminated at each of the different dideoxynucleotides included (A, T, 
C or G) (37; 38). 
The products of the four reactions are separated by electrophoresis on a 
polyacrylamide gel in parallel columns. The synthesized fragments are detected by 
an incorporated, fluorescent or radioactive marker (in the primer or in one of the tri-
phosphate deoxyribonucleotides). Reading the bands in ascending order, beginning 
at the bottom of the gel, the DNA sequence is reconstructed (34; 37; 38). 
 
 
 
 
 
 
 
 
 
 
Figure 7. Illustration of the Sanger dideoxy method for DNA sequencing. Addition of primers, 
DNA polymerase and labeled dideoxyribonucleotides, lacking the 3’ hydroxyl group, to a mix 
of DNA simple strand. Without the 3’ hydroxyl group, reactions are stopped producing a 
group of DNA strands of various sizes. These products are separated by size on 
electrophoresis gels. The labeled nucleotides allow the reading of the sequences over the 
four columns of the gel. See text for explanation.7 
                                                          
7
 Figure drawn by C. Godel (2012).  
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Dye-labeling terminator sequencing 
In the dye-labeling terminator sequencing method, each of the four tri-phosphate 
dideoxyribonucleotides carries a different fluorescent label. This allows sequencing in 
a single reaction rather than four (44-46). This method relies on the use of a modified 
DNA polymerase that accepts the fluorescently labeled dideoxynucleotide as a 
substrate (34). The automation of the dye-terminator sequencing technology by 
Smith et al. (1986) (44) is now, along with high-throughput DNA sequence analyzers 
and next generation sequencing, used for most of the sequencing projects. The 
obtainable sequence length is about 1000 nucleotides (47). 
Automated sequencing and high-throughput sequencing development 
In 1986, Applied Biosystems and the laboratory of Leroy Hood announced a 
revolution in the sequencing world by launching the automated ABI 370A DNA 
sequencer (44). This technology allowed sequencing of expressed sequenced tags 
(ESTs), first successfully done by Craig Venter, as an approach to discover new 
genes. Today the EST database contains over 43 million ESTs from more than 1300 
different organisms (47). 
Craig Venter also introduced shotgun sequencing of whole genomes. This uses 
restriction enzymes or mechanical forces to shear large DNA fragments into smaller 
ones, which are cloned into a vector and amplified in E. coli. Then they are 
individually sequenced and assembled into contiguous sequence (contigs). Gaps in 
the sequence are filled with the PCR (48). 
The assembly is challenging and may be complicated by sequence repeats (49). 
However, the first human genome was sequenced with a shotgun approach (50). 
In the last decades the sequencing speed increased and the costs dropped 
drastically with the invention of new machines and technologies (Figure 8) (51; 62).  
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Figure 8. Decreasing costs to sequence a human genome over 10 years.8  
 
Next generation sequencing technologies comprise 454 sequencing, SOLID, Illumina 
sequencing, Ion Torrent, and PacBio. In the following, I shall concentrate on 454 and 
Illumina, which are presently the most widely used.  
New technologies allow to sequence up to one billion bases in a single day at low 
cost. They lay out millions of DNA fragments on a single chip and sequence all the 
fragments in parallel. However, these new sequencing technologies produce read 
lengths as short as 50-400 nucleotides, increasing the challenge for genome 
assembly (52).  
454-Pyrosequencing 
In 2005, 454 Life Sciences released the first genome sequenced by pyrosequencing, 
the genome of Mycoplasma genitalium (53). The company 454, founded by J. 
Rothberg (54), was purchased by Roche Diagnostics in 2007. 454 sequencing is 
based on real-time pyrophosphate sequencing (55). DNA is fragmented, ligated to 
specific adapters, which serve as binding sites for primers in a polymerase chain 
reaction (PCR) in water droplets in an oil solution, known as emulsion PCR. Each 
droplet contains a single DNA fragment attached to a single primer-coated bead. 
After amplification, the template DNA covered beads are loaded into picolitre-volume 
wells etched into the surface of a fiber optic slide (54; 56), one bead per well. 
                                                          
8 Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Large-Scale Genome Sequencing 
Program Available at: www.genome.gov/sequencingcosts 
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Reaction mix and sequencing enzyme are added. Luciferase is used to generate light 
from ATP, which in turn is built from the pyrophosphate fread upon nucleotide 
insertion (53). The accuracy of the 454 sequencing technology coupled with the 
genome sequencer FLX reaches 99.99%. This technology does not only have a high 
accuracy, it also works fast; producing more than 100 million bases per 8 hour run 
(56). The longest reads are over 1kb in length (57), which will help mapping in 
repetitive regions. The main drawback of this technology is the inability to resolve 
mononucleotide stretches longer than about 8. Pyrosequencing has been involved in 
numerous de novo genome projects as bacterial, fungal and viral genomes, 
sequencing of small RNA populations or sequencing of genome from ancient 
organisms, mammoth (58) or Neanderthal (59).  
Illumina sequencing 
Like the 454 sequencing technology the Illumina genome analyzer is based on the 
concept of “sequencing by synthesis” to produce reads of 36-150 bp from tens of 
millions of surface amplified DNA fragments simultaneously. Using blocked 
nucleotides, it overcomes the mononucleotide stretch problem of 454 and yields over 
a million of high-quality short reads per run totalling several gigabases of aligned 
sequences (62). Illumina sequencing also known as Solexa sequencing (63) used for 
whole genome sequencing, genome resequencing, transcriptomics and small RNA 
identification and quantification (64). The fragments and all four nucleotides are 
added simultaneously to the flow cell channels, along with DNA polymerase, and 
grown in clusters to provide a stronger fluorescent signal (48-49). The sequencing 
reaction takes place in flow cell surfaces which contain oligonucleotides. Flow cell 
surfaces are divided into eight sealed glass lanes where bridge amplification takes 
place on the inside surface. The addition of DNA polymerase to the surface produces 
multiple “polonies” (DNA copies). One cluster contains about a million copies of the 
original fragment (48). For additional details see Figure 9. 
The sequencing workflow of the Illumina genome analyzer is initiated by the fragment 
preparation: random fragmentation of the template DNA and ligation of adapters to 
both ends of the fragment. Then, the DNA single stranded fragments bind to the 
surface of flow cell channels, which are lined with a complementary sequence of the 
adapter. To initiate the bridge amplification, unlabeled nucleotides and DNA 
polymerase are added, resulting in double stranded fragments. A PCR type reaction 
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is performed and several million of DNA clusters are generated in each channel of 
the flow cell (DNA polonies). These are sequenced over multiple cycles adding one 
sort of labeled dNTP per cycle. Laser excitation detects the image in which of the 
polonies the nucleotides were incorporated. Before the initiation of the next chemistry 
cycle, the blocked 3’ terminus and the fluorophore from each incorporated bases are 
removed. Additional chemistry cycles are performed to obtain the complete 
sequencing (48; 60). 
 
Figure 9. Illumina Hiseq. Sequencing workflow of the Genome Analyzer. A. Generation of 
sequencing libraries by random fragmentation of DNA strand and ligation of adapters at both 
ends of the fragment. B. Addition of fragments to the flow cell coated with complementary 
oligonucleotides. It is followed by the formation of bridges by hybridization and the 
amplification of the 3’ to 5’ in order to form clusters. C. A denaturation step occurs followed 
by the addition of primers, polymerase and labeled nucleotides. The surface is imaged and 
the process can be repeated.9  
                                                          
9
 Tucker T. et al. (2009) Massively parallel sequencing: the next big thing in genetic medicine The 
American Journal of Human Genetics 85, 142-147). 
A 
B 
C 
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The Illumina technique is limited by the short read length between 36 to 150 bases. 
However, it is faster and cheaper than other methods. The mate-pair method was 
developed to obtain longer intervals between reads. As an example to demonstrate 
the feasibility of the whole genome shotgun sequencing strategy, the genome of the 
giant panda was sequenced using Illumina Genome Analyzer sequencing technology 
(65). 
Paired-end libraries are short reads and mate-pair reads are between 2 to 5 kb apart 
and thus very helpful for scaffolding (68). 
Third generation of high-throughput sequencing 
The “one-base-at-a-time” sequencing, also named third generation sequencing (68), 
refers to the sequencing from a single DNA molecule and therefore does not need 
any amplification of the DNA template before sequencing (48). 
In 2003, Helicos Biosciences and Braslavsky et al. (70) described and licensed a 
Single Molecule Real-Time (SMRT) technology sequencing a single DNA molecule at 
a time (69). Commercially available in 2007, this method relies on the “true single 
molecule sequencing” (60). The fluorescently labeled nucleotides are detected 
followed by chemical cleavage of fluorophores enabling the next fluorescent labeled 
nucleotide addition and DNA elongation (71). Up to 28 Gb over 8 days can be 
sequenced with this method in a single run with short reads length of 55 bp 
approximately. This technology brings more accurate homopolymer and direct RNA 
sequencing (72). The current accuracy is greater than 99%. Its ability to explore very 
long reads and its fast sequencing speed will dramatically decrease the sequencing 
costs (68). 
Ion semiconductor sequencing, known as Ion Torrent sequencing, came to market in 
2010 (75). The Ion Torrent technology measures the proton which is released upon 
incorporation of a nucleotide into the growing strand of DNA (76-77). The main 
advantages are that it does not require modified nucleosides and fluorescence 
images (which use up enormous amounts of disc spaces).  
Summary and further analysis 
Table 1 summarizes the different high-throughput sequencing methodologies.  
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Table 1. Summary of different methods of high-throughput sequencing and their specific 
characteristics. 
 
Sequencing 
methods 
ABI 3730xl 
Genome 
analyzer 
Roche 454 FLX Illumina 
genome 
analyzer and 
HiSeq 
ABI SOLiD 
(Life 
technologies) 
Helicos 
Biosciences  
Ion Torrent Pacific 
Biosciences 
Platform ABI 3730xl 
Genome 
analyzer 
GS FLX 
Titanium, GS 
Junior 
HiSeq 2000, 
Genome 
Analyzer IIX, 
Genome 
Analyzer IIE, 
iScanIQ 
ABI SOLiD, 
SOLiD4 
HeliScope Ion Torrent ion 
semiconductor 
sequencer 
PACBIO RS 
Sample 
requirements 
 1µg for shotgun 
library, 5µg for 
paired-end 
<1g for single 
of paired-end 
libraries 
<2µg for 
shotgun library, 
5-10µg for 
paired-end 
<2µg, single 
end only 
 10-20 ng for 
whole genome 
amplification, 
500ng for 1kb 
or smaller 
fragments 
Chemistry Automated 
Sanger 
sequencing 
Pyrosequencing 
on solid support 
Sequencing-
by-synthesis 
with reversible 
terminators 
Sequencing by 
ligation 
Reversible dye 
terminators 
Ion 
semiconductor 
sequencing 
Single molecule 
detection by 
light pulses 
emitted as a 
byproduct of 
nucleotide 
incorporation 
 
Method of 
amplification 
of the 
sample 
In vivo 
amplification 
via cloning 
Bead-based / 
Emulsion PCR 
Bridge PCR Bead-based / 
Emulsion PCR 
Single 
molecule 
sequencing 
Emulsion PCR Single molecule 
sequencing 
Template 
preparation 
 Clonal-ePCR 
on bead surface 
Clonal bridge 
enzymatic 
amplification 
on glass 
surface 
Clonal-ePCR 
on bead surface 
Single 
molecule 
detection 
 Single molecule 
detection 
Detection 
method 
 Light emitting 
from secondary 
reactions 
initiated by 
release of 
pyrophospate 
Fluorescent 
emission from 
incorporated 
dye-labeled 
nucleotides 
Fluorescent 
emission from 
ligated dye-
labeled 
oligonucleotides 
Real-time 
detection of 
fluorescent dye 
in polymerase 
active site 
during 
incorporation 
Real-time 
detection of 
released 
hydrogen ions 
by ion sensor 
Real-time 
detection 
Read lengths 700-1000 bp 500-1000 bp 36-150 bp 35-75 bp 55 bp 200bp 200bp -10kb 
Accuracy  99.99% >98.5% 99.99% >99% 99.6% 99.999% 
Total 
throughput, 
bases per 
run 
 0.40-0.60 Gb 3-6 Gb 10-20 Gb 
(180Gb per run) 
28 Gb 100 Mb 3Gb 
Run time 2Mb / day 8 hours 4-9* days 7-14* days 8 days 1.5 hours 30min to 1 day 
Pros  Long reads 
helps mapping 
in repetitive 
regions; quick 
runs 
Most broadly 
used 
Two-base 
encoding 
provides 
inherent 
correction error. 
High accuracy 
due to two-base 
encoding 
technology 
No 
amplification 
required, lower 
cost, more 
accurate 
homopolymer 
and direct RNA 
sequencing 
Rapid 
sequencing 
speed, low 
costs, small 
bench 
machine 
Longer reads 
length, rapid 
sequencing 
speed, easy 
use, protocol 
flexibility, low 
costs 
Cons Less 
sequences 
generated, 
considerably 
more 
expensive 
High costs 
(reagent) and 
high error rate 
in homopolymer 
repeats 
Low 
multiplexing 
capability of 
samples 
Long run time Asynchronous 
sequencing, 
higher raw 
error rate 
increasing the 
cost per base 
Difficult to 
enumerate 
long repeats, 
short read 
length and low 
throughput 
Quite new 
technology so it 
is hard to 
define cons.  
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Use  Whole genome, 
transcriptome, 
metagenome 
and deep 
sequencing 
Whole 
genome or 
targeted 
resequencing, 
transcriptome, 
gene 
regulation, de 
novo and 
metagenomics 
analysis 
Whole genome 
resequencing 
(fragment 
library or mate-
pair library), 
comparative 
resequencing, 
enrichment 
technology, 
comparative 
transcriptomic 
sequencing 
Whole genome 
resequencing, 
transcriptome 
resequencing 
and analysis, 
small RNA 
sequencing, 
Quantitative 
polyadenylation 
site 
mapping/Digital 
Gene 
Expression,... 
 
Small scale 
applications 
(microbial 
genome 
/transcriptome 
sequencing, 
targeted or 
amplicon 
sequencing, 
quality testing  
Whole genome 
amplification, 
target 
resequencing, 
pathogen 
application, 
transcript 
analysis, can 
resolve SNPs 
and large scale 
structural 
rearrangements 
References 78, 79, 81 49, 56, 60,  62, 
80, 81, 82 
49, 60, 62, 80, 
81, 84 
49, 60, 61, 62, 
80, 81, 83 
61, 70, 72, 85, 
86, 88 
87 73, 74, 89 
 
Assembly methods 
The first step after sequencing is usually a check of the reads, discarding short or 
ambiguous reads. Then the reads that pass the quality check need to be assembled 
into contigs, and these into scaffolds. In theory, read assembly is perfectly solvable 
by alignment algorithms. In praxis, however this fails because of the enormous 
numbers of reads. Today, the most efficient assemblers rely on graphs where the 
reads (= nodes) are linked by common words (k-mers = edges). The most of these 
assemblers consider the reads as network called a graph. The mainly used short 
read assemblers are Velvet (de Bruijn graph methods), SOAPdenovo, Forge or 
ABySS. The field is developing very fast. The quality of the assembly is measured 
based on different criteria, such as the contig size distribution (N50, longest 
contig/scaffold), the number of bases in contigs, length of the longest contig, etc.  
The algorithms for assembly are based on Eulerian paths, Hamiltonian paths, or both 
(de Bruijn path). Leonhard Euler is a Swiss mathematician who founded graph theory 
by solving the problem of the seven bridges of Könisberg in 1736. An Eulerian path 
visits every edge (link) in a graph exactly once. In practice, it is much more 
complicated to construct a Hamiltonian path, which visits every vertex (node) exactly 
once.   
Velvet uses the De Bruijn graph methods as do most of the next-generation 
sequencing assemblers. A de Bruijn graph reduces the computational effort by 
breaking reads into k-mers; the parameter k denotes the word length (90; 91). The de 
Bruijn graph captures perfect overlaps of length k-1 between these k-mers and not 
between the actual reads (92). The best k-mer size for a particular assembly is 
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determined empirically. Repeats in the genome are collapsed (92). However, some of 
the collapsed repeats could be biologically meaningful. 
ABySS (Assembly By Short Sequences) uses a distributed representation of the de 
Brujin graph. The technology is based on a two stage algorithm, generation of k-mers 
from the sequence reads and building of contigs, and extension of the contigs based 
on sequence pairs (93).  
Example of de novo genome sequencing 
More and more sequenced genomes become available due to the drastic drop of the 
cost and time of sequencing. Table 2 lists species with fully sequenced genome. 
Most of the bigger genomes have been still sequenced by classical Sanger 
sequencing but this is changing.  
 
Table 2. Comparison between various animal species of the genome size, number of 
annotated ligand-gated ion channels and the sequencing method for the genome studies.  
 
Species Phylum NGS Coverage Genome 
(Mb)  
LGIC Genome 
status 
References 
Dirofilaria 
immitis  
Nematoda 
Clade III 
HiSeq2000 
(Illumina) 
~170-fold ~90 24 Draft This work 
Brugia malayi Nematoda 
Clade III 
Whole 
Genome 
Shotgun 
~9-fold ~95 24 Complete (108) (113) 
Onchocerca 
volvulus 
Nematoda 
Clade III 
Genome 
Analyzer II 
(Illumina) 
//Roche 454 
- 25.99 ? In 
progress 
(98) (99) 
(101) 
Caenorhabditis 
elegans 
Nematoda 
Clade V 
Fingerprint – 
clones/Solexa 
~20-fold 100 84 Complete (95)(96) 
Ascaris suum Nematoda 
Clade III 
HiSeq2000 
(Illumina) 
~80-fold 273 5 Draft (97) 
Meloidogyne 
hapla 
Nematoda 
Clade IVb 
ABI 3730 and 
MegaBase 
Sequencers 
10.4 54 32  (94) 
Haemonchus 
contortus 
Nematode 
Clade V 
HiSeq2000 
(Illumina) 
- 60 41 In 
progress 
(98) 
Schistosoma 
mansoni 
Platyhelminth 
Trematoda 
Genome 
Analyzer II 
(Illumina) 
~6-fold 270 13 Draft (98) 
Echinococcus 
multilocularis 
Platyhelminth 
Cestoda 
Genome 
Analyzer II 
(Illumina) 
- 150 13 In 
progress 
(98) 
Danio rerio Vertebrata  ~21-fold 1500 56 Draft (98) (107) 
Xenopus 
tropicalis 
Vertebrata High shotgun 
seq 
~7.6-fold 1500 ? 38 Draft (106) 
Homo sapiens 
sapiens 
Vertebrata Whole 
Genome 
Shotgun 
/Sanger /454 
~7.4-fold 2865 36 Draft (110) (112) 
Canis familiaris Vertebrata High shotgun 
seq 
~7.5-fold 2041 36 Draft (100) 
Felis catus Vertebrata High shotgun 
seq 
~1.9-fold ~3000 21 Draft (109) 
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Drosophila 
melanogaster 
Diptera Whole 
Genome 
Shotgun 
~23-fold 180 21 Draft (103) 
Aedes aegypti Diptera Whole 
Genome 
Shotgun 
~12-fold 1376 16 Draft (105) (111) 
Anopheles 
gambiae 
Diptera Whole 
Genome 
Shotgun 
~10.2-fold 260 20 Draft (104) 
Culex 
quinquefasciatus 
Diptera Whole 
Genome 
Shotgun 
- 540 19 In 
progress 
(102) 
Anthelmintics and targets 
A major driving force for the sequencing of pathogen genomes has been the 
identification of novel drug targets. Until now, however, empirical screening for new 
drugs has been more successful than rational, post-genomic approaches.   
 
Most current anthelmintics target the ion channels. Avermectins hyperactivate 
glutamate chloride gated channels, Cyclodeopsipeptides activate the SLO-1 K+ 
channel, Imidazothiazoles and AADs hyperactivate the nAChR and Praziquantel 
inhibits calcium channels (Figure 10). The next paragraph will focus on the ligand 
gated-ion channels and in particular on nAChR.  
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Figure 10. Illustration representing the mode of action and localization of numerous different 
anthelmintics at the neuromuscular junction. The different class of drug represented have 
specific mode of action, targeting for example tubulins for the benzimidazoles, calcium 
channels for the cyclodepsipeptides and chloride gated channels for avermectins. Related to 
each class, some drug names are given as example.10 
 
                                                          
10
 C. Godel (2012) , unpublished. 
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Nicotinic acetylcholine receptors and cys-loop ligand-gated ion channels 
Ligand-gated ion channels (LGIC) are widely spread across the Kingdom animals, 
bacteria, unicellular eukaryotes and plants. The importance and pharmacological 
potential of LGIC in animals is demonstrated by the fact that many natural toxin act 
on them. The superfamily of cys-loop ligand-gated ion channels represents the most 
important targets of the current anthelmintics in parasitic nematodes (114-115).  
Nicotinic acetylcholine receptors belong to the class of the LGIC as well as serotonin 
5-HT, GABAA and GABAC, and glycine receptors (117-118). 
Located in postsynaptic membranes of central nervous system synapses and at the 
neuromuscular endplates, the nAChR are cholinergic receptors forming ion channels 
activated by acetylcholine but also nicotine. These glycoproteins are cation channels 
selective for Na+, K+ and less frequently to Ca2+. The channels structure is 
pentameric with 2 α, one β, γ, and δ subunit surrounding a central pore. The subunits 
are named in relation to their increasing molecular weights. The channels open by 
extra-cellular binding of a chemical messenger (agonist). The nicotinic acetylcholine 
receptors are the link between nerve cell and muscle fiber. When a receptor is 
stimulated by a chemical messenger, it causes depolarization muscular contractions 
by opening the channel. This muscular stimulation is caused by the flow of cations 
through the receptor after the binding of neurotransmitters. The signal activated by 
the neurotransmitter is received from the pre-synaptic neuron (116). The pentameric 
glycoprotein presents a cys-loop, a cysteine doublet in the N-teminal part that 
participates in the acetylcholine (ACh) binding site. The receptor is divided into nine α 
neuronal subunits encoding the nAChR additionally to the three β subunits (119-120). 
Next to the cys-loop the nAChR possess four specific, conserved transmembrane 
domains (TMI-TMIV). The receptor is structurally divided in two main parts; the 
ligand-binding domain with a long extracellular N-terminal chain presenting the 
glycolysation sites, and the large transmembrane channel domain, about 100-200 
amino acids, phosphorylation sites between TMIII and TMIV and a short C-terminal 
domain about 4-28 amino acids (117-118). The nicotinic acetylcholine receptors are 
illustrated in Figures 11 and 12. 
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Figure 11. Schematic representation of nicotinic acetylcholine receptors protein with the four 
transmembrane domains (M1-M4), the extracellular chain with the N-terminal and 
glycolysation sites and the intracellular domain with the cys-loop. 11 
 
The free-living nematode C. elegans is the model worm for parasitic species and has 
the most LGIC genes of any known organism. With the growing numbers of 
sequenced genomes available, phylogenomic studies are possible of LGIC families in 
diverse species. As an example, in 2007 Williamson et al. presented the LGICs of 
Brugia malayi and Trichinella spiralis (120). For both parasites showed fewer LGIC 
than C. elegans. Rufener et al. (2010), illustrated the phylogeny of LGIC genes of 
nematodes, vertebrates, insects and platyhelminths, based on the lingand binding 
domains (29). This paper correlated the inventory of LGIC genes with monepantel 
susceptibility. All the monepantel sensitive species possessed an ACR-23 or MPTL-1 
ortholog, the presumed target of AADs (121). The LGIC inventory of the heartworm, 
however, is a black box since no single LGIC has been cloned from D. immitis. The 
closely related filaroidea B. malayi does not possess any ortholog to acr-23. 
However, deg-3 and des-2 genes are present (108; 121); they may play a role in the 
mode of action of the AAD. 
 
 
 
 
                                                          
11
 Schematic representation of the nAChRs. (78) (Hucho F. and Weise C. (2001) Ligand-gated ion 
channels Angew. Chem. Int. Ed. 40:3100-3116) 
I n t r o d u c t i o n   P a g e  | 35 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Pentameric nicotinic acetylcholine receptor. The neurotransmitter binds to the 
receptor and allows the cation flow through the channel causing muscular contractions.12  
                                                          
12
 http://chemweb.calpoly.edu/cbailey/377/PapersSp2000/Kevin/nicotine.html 
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Aims and objectives 
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The main goal of this PhD project was to identify and characterize potential drug 
targets in the animal parasitic nematode, Dirofilaria immitis. Of particular interest 
were ligand-gated ion channels of the DEG-3 subfamily as potential targets of 
monepantel. 
The specific objectives were chronologically (1) to standardize and implement in vitro 
drug sensitivity tests with D. immitis, (2) to sequence the genome of D. immitis and 
predict its proteome in particular and (3) to identify target LGIC, characterize these in 
silico based on phylogenetic comparisons, (4) potential drug targets to correlate the 
drug susceptibility with the presence or absence of the predicted target(s).  
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Parasite chemotherapy has a simple rationale: to kill the pathogen but not its host by applying 
compounds of selective toxicity. The possibility of selective activity was first inferred by Paul Ehrlich 
who, graduating in histology in 1887, had observed that certain organic dyes exhibit greater affinity 
for parasites than for host cells. Ehrlich concluded that selective antiparasitic chemotherapy is 
possible if such dyes are cytotoxic, and only four years later he put the idea into practice by 
successful treatment of two malaria patients with methylene blue (Guttmann et al., 1891). Ehrlich 
coined the term chemotherapia specifica, also known as magic bullet, for a chemical compound like 
methylene blue that exhbits discriminating activity against the pathogen and thus opens a 
therapeutic window for treatment of an infected host. The degree of selectivity of a drug in vivo is 
expressed as the therapeutic index, the LD50 of a drug divided by its ED50 (where LD50 is the lethal 
dose that kills 50% of test animals and ED50 is the effective dose which cures 50% of the test animals). 
The larger the therapeutic index, the greater the margin of safety. To a first estimate the selectivity 
of a drug may also be assessed in vitro by comparing its 50% inhibitory concentrations (IC50) towards 
parasites and mammalian cells (Kaminsky et al., 1996). Table 1 shows the in vitro selectivities of 
selected parasiticides as determined in our laboratory. Some of the drugs have selectivity indices of 
several hundreds or thousands. What is the molecular basis of such striking parasite-specific activity? 
Here we try to dissect the molecular mechanisms of antiparasitic drug selectivity. Concentrating on 
the nature of the difference between the drug target in the parasite and its closest orthologue in the 
mammalian host, we distinguish six different scenarios (A to F, summarized in Table 2) which create 
opportunities for antiparasitic drug selectivity, all of which are documented by examples of 
antiparasitic drugs. 
A) There is no orthologue of the antiparasitic drug target in the host proteome. This scenario 
corresponds to the classical definition of an antibiotic drug target, i.e. an enzyme that is essential to 
the pathogen but absent in the host. The most prominent example comes from prokaryotes: 
transpeptidase, the target of penicillin. Transpeptidase builds the stabilizing cross-links in the murein 
cell wall of bacteria. Mammals lacking murein as well as transpeptidase, they are not susceptible to 
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penicillins. Absence of a human orthologue is a criterion that fits antibacterial drug targets in 
particular, given the large evolutionary distance between host and pathogen. However, drug targets 
of bacterial origin also occur in eukaryotic parasites: in endosymbionts or remnants thereof. 
 Wolbachia are obligate intracellular bacteria which colonize arthropods and filarial 
nematodes (Saridaki et al., 2010). Living in tight association with their host cell, Wolbachia display 
reduced genomes and may represent a transitory stage between parasite and symbiont. While in 
arthropods, Wolbachia frequently exert harmful effects including male-killing and cytoplasmic 
incompatibility (Saridaki et al., 2010), their relationship with nematodes is mutualistic. Wolbachia 
possibly provide parasitic nematodes with purines and heme, and they are required for the 
maturation of oocytes. Doxycycline treatment of dogs infected with the heartworm Dirofilaria 
immitis reduced the numbers of circulating microfilariae, caused degeneration of oocytes in adult 
female, and necroses in adult male worms (Bazzocchi et al., 2008). However, the doxycycline 
treatment did not completely clear the Wolbachia from D. immitis (Bazzocchi et al., 2008; Rossi et al., 
2010). The Wolbachia genomes of Brugia malayi (Foster et al., 2005) and D. immitis (Godel et al., 
submitted) encode for about 800 predicted proteins. Many of these are likely to be essential – for 
the simple reason that if not, they would have been lost in the course of evolution. Potential 
antifilarial drug targets encoded by endosymbiont Wolbachia comprise the cell division protein FtsZ 
(Li et al., 2011), phosphoglycerate mutase (Foster et al., 2009), pyruvate phosphate dikinase (Raverdy 
et al., 2008) and, somewhat surprisingly for an intracellular bacterium, also the gene products of the 
mur operon for murein biosynthesis (Godel et al., submitted). 
 Drug targets of bacterial origin are also found in the phylum Apicomplexa, which contains the 
causative agents of malaria, toxoplasmosis, babesiosis, east cost fever and coccidioses. All these 
parasites possess an apicoplast, the remnant of a secondary endosymbiont as indicated by the four 
surrounding membranes and bipartite targeting signals of imported proteins (Foth et al., 2003). Only 
the innermost compartment contains DNA, which is of prokaryotic provenance. The metabolic 
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pathways in the apicoplast of Plasmodium falciparum were reconstructed in silico based on the 
prediction of import signals (Foth et al., 2003; Ralph et al., 2004). Promising antimalarial targets in 
the apicoplast are enzymes of the deoxyxylulose-phosphate (i.e. non-mevalonate) pathway for 
isoprenoid synthesis such as DOX-P reductoisomerase, the target of fosmidomycin (Jomaa et al., 
1999) (Table 2). Enzymes of the type II pathway for fatty acid synthesis have been proposed as drug 
targets too; however, initial reports of triclosan efficacy in a malaria mouse model (Surolia et al., 
2001) were not reproducible later on (Baschong et al., 2011). 
 There is a number of further target proteins, besides those that are relics from prokaryotes, 
which are absent from mammals but essential to parasites. The presence of the folate synthetic 
enzymes dihydropteroate synthase (EC 2.5.1.15) and dihydrofolate synthase (EC 6.3.2.12) in 
Plasmodium spp. and other apicomplexans renders them susceptible to sulfonamides. 
Trypanosomatids possess a variety of biochemical peculiarities (Opperdoes, 1985) which lend 
themselves to chemotherapeutic intervention: trypanothione and ergosterol are shown in Figure 1. 
While initial leads against T. cruzi were azoles targeting Δ24 sterol methyl transferase (E.C. 2.1.1.43) 
(Urbina et al., 1996), presently the most promising candidates for new drugs against T. cruzi are 
triazole inhibitors of cytochrome P-450-dependent C14 sterol demethylase (CYP51) (Urbina, 2009). 
Ergosterol in their membranes is also thought to render Leishmania susceptible to amphotericin B, 
enabling the docking of amphotericin B and formation of pores (Ramos et al., 1996). Chitin synthesis 
is another pathway of pharmacological importance. Chitin is made by a plethora of pathogens and 
pests including fungi, nematodes, and arthropods (Figure 1) but not by mammals. Inhibitors of chitin 
synthase (EC 2.4.1.16) therefore have a great potential as broad-spectrum parasiticides.  Lufenuron is 
used in the veterinary sector against fleas and heartworm, nikkomycin Z is in clinical development for 
human mycoses (Chaudhary et al., 2012).  
B) There is an orthologous target in the host, but it is less sensitive. Tubulins fulfill essential 
functions in cell division and vesicular trafficking in all eukaryotic cells, and belong to the most 
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conserved proteins of eukaryotes. The β-tubulins 2B from Homo sapiens (NP_821080) and tbb-4 
from Caenorhabditis elegans (NP_509585), for instance, are over 93% identical. And yet, 
benzimidazole drugs selectively bind the C. elegans protein, blocking the polymerization of 
microtubules in nematodes but not in mammals. Benzimidazoles are widely used against 
phytopathogenic fungi, gastrointestinal nematodes of lifestock, soil-transmitted helminths of 
humans, cestodes, and Giardia intestinalis. Drug resistance studies have demonstrated that a single 
point mutation in a nematode β-tubulin, phenylalanine-200 to tyrosine (Kwa et al., 1994), suffices to 
convey benzimidazole resistance (Kwa et al., 1995). The same mutation was also reported from 
benzimidazole resistant field isolates of phytopathogenic fungi (Ma et al., 2003; Banno et al., 2008; 
Suga et al. 2011). Intriguingly, mammalian β-tubulins naturally carry a tyrosine at position 200, 
suggesting that a single hydroxy group determines over drug susceptibility. Tyrosine-200 was 
proposed to be involved in a hydrogen bond preventing benzimidazoles from binding to β-tubulin 
(Robinson et al., 2004). Additional point mutations described from benzimidazole resistant 
nematodes and fungi line out the presumed benzimidazole-binding pocket of β-tubulin (Robinson et 
al., 2004). In particular, mutation of glutamate-198 (which is conserved in nematodes and fungi) to 
alanine was found in high-level resistant isolates (Ma et al., 2003; Ghisi et al., 2007; Rufener et al., 
2009). 
C) There is an orthologous target in the host proteome, but it is not essential. This is a rather 
theoretical possibility which is poorly supported by actual drugs. Purine interconversion enzymes 
might be candidate targets.  Since all obligate endoparasitic protozoa studied so far lack the enzymes 
for purine de novo synthesis; presumably, the corresponding genes were lost in adaptation to a 
parasitic lifestyle. The mammalian host being able to make purines de novo, the salvage is unlikely to 
be essential. However, due to the high degree of redundancy in purine interconversion pathways, 
parasite are unlike to be essential either. Even in Toxoplasma gondii, whose purine metabolic 
network is very simple, knock-out parasites of single purine salvage genes were still viable 
(Chaudhary et al., 2004). One example for an enzyme that is a drug target because it is essential to 
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the pathogen but not to the host is reverse transcriptase. This enzyme is an attractive antiretroviral 
drug target that is also encoded in the human genome, in retrotransposons (de Parseval et al., 2005). 
'Human' reverse transcriptases are unlikely to be essential, even though the enzyme has been 
implicated in repair of chromosomal breaks (Teng et al., 1996). 
D) There is an orthologous, sensitive target in the host, but it is less accessible. Drug transport 
phenomena are increasingly being recognized as determinants of drug susceptibility (Dobson et al., 
2009; Lanthaler et al., 2011). The presence or absence of a particular transporter may decide on 
whether a drug reaches its target tissue, cell, or subcellular compartment. The importance of drug 
transport was illustrated in a tragical way by the pyrimidine analogue fialuridine, which had been in 
clinical development as an antiviral agent. Fialuridine had a inconspicuous safety profile in the tested 
animal models but killed five hepatitis B patients in a clinical trial (McKenzie et al., 1995). The reason 
for the selective toxicity turned out to be the presence of the nucleoside transporter ENT1 in the 
human mitochondrial inner membrane, importing fialuridine into mitochondria (Lee et al., 2006). The 
toxicity of fialuridine could not be anticipated in mice since the mouse ENT1 orthologue does not 
carry a mitochondial targeting signal. 
 Another example of how the absence of a transporter may be protective is provided by the 
melamine-based arsenical melarsoprol, still the only approved therapy for the treatment of late-
stage T. b. rhodesiense sleeping sickness. Melarsoprol and its metabolite melarsen oxide are mainly 
imported into trypanosomes via an aminopurine permease termed P2 (Carter et al., 1993), encoded 
by the gene TbAT1 (Mäser et al., 1999; Geiser et al., 2005). The absence of an aminopurine-selective 
transporter from mammalian cells may contribute to the therapeutic window of melarsoprol. 
Homozygous deletion of TbAT1 reduced the sensitivity of T. b. brucei to melarsoprol (Matovu et al., 
2003), but not to the membrane-permeable phenylarsine (Lüscher et al., 2006b). Expression of 
TbAT1 in Saccharomyces cerevisiae rendered the transformants susceptible to melarsen (Mäser et 
al., 1999). The amidine-based substrate recognition motif of TbAT1 was mapped (de Koning et al., 
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1999; Lüscher et al., 2006a), and covalent linkage of a P2-recognition haptophore (sic Ehrlich) such as 
melamine was proposed to selectively deliver toxophores to trypanosomes (Tye et al., 1998; Barrett 
et al., 2006). 
 Transport barriers may also decide over drug susceptibility. The mammalian brain is 
protected from hydrophobic xenobiotics by P-glycoprotein, a detoxification efflux pump expressed 
by the endothelial cells of the blood-brain barrier. Among the many substrates of P-glycoprotein is 
also ivermectin. Ivermectin is a semisynthetic avermectin that activates glutamate-gated chloride 
channels of the postsynaptic membrane in helminths and arthropods, thereby hyperpolarizing the 
target cell (Dent et al., 2000; Yates et al., 2004). Mammals do not possess such channels. However, 
ivermectin also acitvates the GABA-gated chloride channels of the mammalian brain (Adelsberger et 
al., 2000; Wolstenholme). Thus the principal reason for the selectivity of ivermectin appears to be 
that ivermectin is a P-glycoprotein substrate and cannot reach its targets in the mammalian brain. 
The protective role of P-glycoprotein is highlighted by the fact that MDR1 deficiency in dogs is linked 
to ivermectin toxicity (Wolstenholme, 2010). Homozygous deletion of MDR1 caused ivermectin 
hypersusceptibility also in mice (Schinkel et al., 1994). In parasitic nematodes, ivermectin resistance 
was accompanied by loss of heterogeneity at a nematode P-glycoprotein locus (Blackhall et al., 1998; 
Xu et al., 1998). 
E) There is an orthologous, sensitive, and accessible target in the host, but it is replenished. 
Dihydrofolate reductase, required to make thymidine from uridine, is an essential enzyme in all cells. 
Plasmodium falciparum DHFR is the target of the antimalarial pyrimethamine (combined with 
sulfadoxine to Fansidar). The in vitro selectivity index of pyrimethamine (Table 1) is much larger than 
would be anticipated from the different affinities of recombinant DHFR enzymes from H. sapiens and 
P. falciparum (Zhang et al., 2002). The intricate regulation of DHFR was shown to contribute to the 
hypersensitivity of P. falciparum to inhibitors. Mammalian as well as Plasmodium DHFR levels are 
under the control of negative feed-back: the protein binds its own mRNA, preventing it from being 
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translated (Zhang et al., 2002). This block is releived upon inhibition of human DHFR by folate 
analogues such as pyrimethamine, because the active site of the enzyme participates in binding of 
the mRNA. This is not the case for P. falciparum DHFR, which continues to bind its mRNA even when 
inhibited by pyrimethamine. P. falciparum expressing human DHFR were as tolerant to DHFR 
inhibitors as human cells (Zhang et al., 2002). 
F) A prodrug is only activated in the parasite. Nucleoside and nucleobase analogues are used as 
antiviral and anticancer drugs; many are also active against protozoan parasites. Typically nucleoside 
or nucleobase analogues need to be converted to the corresponding nucleotides. Once in the 
nucleotide pool, the analogues may inhibit nucleic acid polymerases or be mis-incorporated into 
nucleic acids themselves. Thus nucleoside kinases and nucleobase phosphoribosyltransferases are 
activating enzymes and potential determinants of drug susceptibility. This was demonstrated for 
Toxoplasma gondii, where inosine analogues were identified that are subversive substrates of T. 
gondii adenosine kinase but not of human adenosine kinase (Yadav et al., 2004; Al Safarjalani et al., 
2010). The identified compounds were selectively toxic to the parasites (el Kouni et al., 1999). 
Adenosine kinase is of pharmacological importance also in trypanosomes since RNAi-mediated 
silencing of adenosine kinase in T. brucei reduced the sensitivity to cordycepin (3'-deoxyadenosine) 
and adenine arabinoside (Lüscher et al., 2007; Vodnala et al., 2008). 
 The nitroimidazoles are a widely used class of prodrugs. Fexinidazole and nifurtimox are used 
against Trypanosoma spp., metronidazole against Giardia, Trichomonas, and Entamoeba. 
Nitroimidazoles need to undergo single electron reduction to become active, converting to –NO2 
group to the –NO2
-· radical (Figure 2). This requires a strong reducing agent to produce the 
nitroradical anion and an anaerobic environment to prevent its re-oxidation in a futile cycling process 
(Tocher, 1997). The nitroradical anion then reacts with thiol groups, covalently attaching the drug to 
target proteins. In Entamoeba histolytica and Trichomonas vaginalis, thioredoxin reductase was 
shown to be activator and target of metronidazole at the same time (Leitsch et al., 2007; Leitsch et 
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al., 2009). T. vaginalis mutants selected for metronidazole resistance had lost thioredoxin enzymatic 
activity, probably as a consequence of lack of the cofactor flacin adenine dinucleotide (FAD) as the 
susceptibility was restored upon exogenous addition of FAD (Leitsch et al., 2009). Trypanosomatids 
possess NADH-dependent, bacterial-like type I nitroreductase in their mitochondrium, which are 
thought to be crucial for the activation of 'nitro-drugs' such as benzimidazole, nifurtimox, and 
fexinidazole. Selection for nifurtimox resistance in T. cruzi (Wilkinson et al., 2008) and T. brucei 
(Baker et al., 2011) resulted in loss of nitroreductase, and heterozygous deletion of the NTR gene in 
T. brucei conferred nifurtimox resistance (Wilkinson et al., 2008). Mammalian cells, like most 
eukaryotes, do not possess type I nitroreductases (Tweats et al., 2012). 
 Another prominent class of parasiticides that are activated by reduction are the artemisinins. 
Semi-synthetic artemisinins are used as antimalarials and they are also active against schistosomes 
(Xiao et al., 1989; Utzinger et al., 2007). The characteristic feature of artemisinins is their 
endoperoxide bridge. Opened by chemical reduction, it creates radicals that alkylate heme and 
target proteins. The reducing agent is thought to be Fe2+ heme resulting from hemoglobin digestion 
in the parasite's food vacuole (Fügi et al., 2010). This would explain the selective activity of 
artemisinins against hemoglobin-feeders such as the Plasmodium spp. and Schistosoma spp. 
However, this model was challenged by the finding that the in vitro efficacy of artemisinin against P. 
falciparum increased under a 2% carbon monoxide atmosphere (Parapini et al., 2004). 
Conclusion. In summary, the question of how a drug can selectively kill the endoparasite but not the 
host has at least six mechanistically different answers. Importantly, not all of them are approachable 
in silico. Comparative genomics between host and parasite is best suited to detect cases of scenarios 
A and F (Table 2). Most straightforward are targets originating from a bacterial endosymbiont, such 
as those in the apicoplast or in Wolbachia; these are readily recognized based on phylogeny or signal 
sequences, and likely to be essential since they have been preserved during evolution. Other proven 
antiparasitic targets, in particular those of scenarios D and E, can hardly be predicted by 
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bioinformatics and are usually found through cell-based screening. We conclude that it is 
theoretically impossible to replace phenotypic screening with comparative and structural genomics, 
and advocate carrying out the different approaches in parallel in order to maximize the likelyhood of 
discovering novel kinds of parasiticides. 
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TABLES 
Drug Target parasite IC50 against 
target parasite 
[μg/ml] 
IC50 against L6 
fibroblasts 
[μg/ml] 
In vitro 
selectivity 
Chloroquine P. falciparum 0.0030 34 11,000 
Mefloquine P. falciparum 0.0034 3.1 910 
Pyrimethamine P. falciparum 0.0047 3.0 640 
Artemisinin P. falciparum 0.0020 99 49,000 
Melarsoprol T. b. rhodesiense 0.0025 7.3 2,900 
Pentamidine T. b. rhodesiense 0.00082 2.3 2,800 
Nifurtimox T. b. rhodesiense 0.31 37 120 
Fexinidazole T. b. rhodesiense 0.61 88 150 
Metronidazole G. duodenalis 0.49 79 160 
Albendazole G. duodenalis 0.25 0.11 0.44 
 
Table 1. Selected parasiticides and their in vitro activities against the blood-stages of P. falciparum 
(strain NF53) and T. b. rhodesiense (STIB901), G. duodenalis (G1) trophozoites, and R. norvegicus 
fibroblasts (L6). IC50 values were determined after 72 h of incubation in serial drug dilutions using the 
redox dye Alamar blue as an indicator of cell number and viability (Räz et al., 1997). 
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The drug target in the host is ... 
 
A) absent Sulfadoxin 
Fosmidomycin 
Azoles 
Nikkomycin Z 
=> 
=> 
=> 
=> 
Dihydropteroate synthase 
DOXP reductoisomerase 
Ergosterol synthesis 
Chitin synthase 
 
B) not essential Didanosine => Reverse transcriptase 
 
C) less sensitive Benzimidazoles => ß-Tubulin 
 
D) less accessible Ivermectin 
Melarsoprol 
=> 
=> 
Ligand-gated ion channels 
Diverse intracellular targets 
 
E) replenished Eflornithine 
Pyrimethamine 
=> 
=> 
Ornithine decarboxylase 
Dihydrofolate reductase 
 
F) conserved, but the 
drug is not activated 
Nifurtimox 
Artemisinin 
Metronidazole 
<= 
<= 
<= 
Nitroreductase type I 
Fe (II) heme 
Thioredoxin 
 
 
Table 2. Molecular mechanisms of antiparasitic drug selectivity. 
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FIGURES  
 
Figure 1. Essential and parasite-specific metabolites and their closest structures in mammalian cells. 
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Figure 2. Parasite-specific activation of prodrugs. Several of the currently used parasiticides are 
prodrugs that are only activated inside the parasite. 
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Chapter 2. Efficacy testing of AADs 
against D. immitis (unpublished) 
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An in vitro drug sensitivity assay for D. immitis was developed (122) and further 
refined here. In brief, microfilariae are isolated from infested dogs and incubated in a 
medium developed from Hank’s Balanced Salt Solution (HBSS) for up to 72 hours. 
The efficacy, absence of motility, was measured by the evaluation of AADs against 
microfilariae of D. immitis and Acanthocheilonema viteae after 72 hours of incubation. 
Preliminary in vitro tests were performed with the AAD, Monepantel. It showed 
activity against the microfilariae of the filarial nematodes D. immitis and of the model 
parasite, A. viteae. L3 of A.viteae were also sensitive in vitro to monepantel. 
There was activity at 1 ppm each for A. viteae microfilariae and L3 and D. immitis 
microfilariae (Figure 13). 
There was also a high activity of monepantel in the LDA (larval development assay) 
(123), against Trichostrongylus colubriformis, at 0.01 ppm. This is a standard test for 
the current selection of compounds described by Gill at al (123). It assesses drug 
efficacy during the development from egg to L3. 
The in vitro tests showed good efficacy against filarial nematodes, A. viteae and D. 
immitis. However, in vivo in the gerbil Meriones unguiculatus, monepantel exhibited 
no antifilarial activity (Figure 13). 
Milbemycin oxime, a ML, was used as a positive control. Milbemycin oxime is used 
as a preventive against heartworm disease; medication as Sentinel® combined with 
praziquantel and lufenuron, and Interceptor®, in combination with Praziquantel.  
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Figure 13. Monepantel (AAD 2225) activity (EC 90) in four in vitro tests (absence of motility) 
and one in vivo test. Concerning the in vitro tests, the efficacy against microfilariae or L3 is 
evaluated after 48 hours of incubation with the compounds. In the LDA, egg to L3, the 
incubation time is longer with duration of seven days. The results are represented in ppm 
(particle per million). In vivo, compounds are applied per os at 40 mg/kg. The efficacy is 
evaluated at necropsy, by count of the adult parasites. Efficacy is defined by comparison to 
positive control, milbemycin oxime, and a low concentration in ppm.  
 
In further studies, 29 AADs were evaluated against microfilariae in vitro. Ivermectin 
and milbemycin oxime were used as positive controls; albendazole, as negative 
control and a benzithiazole compound was included as well. The aim was to compare 
the in vitro efficacy of these 29 AADs with existing results against similar or different 
parasites.  
The choice of the compounds was based on chemical structure, availability and 
efficacy against gastro-intestinal nematodes. The test was validated by the good 
efficacy of the positive controls, ivermectin and milbemycin oxime. 
The AADs exhibited global efficacy against microfilariae of D. immitis and A. viteae in 
vitro (Figure 14). Microfilariae of D. immitis and A. viteae have more or less similar 
sensitivity. There was a mean efficacy of 82.75% of all AADs.  
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However, only a small number of compounds showed activity in vivo, even if they had 
shown high activity in vitro.  
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Figure 14. In vitro efficacies, EC 90, of AADs against D. immitis and A. viteae microfilariae; 
the tests were performed in triplicates. Results are represented in ppm (particle per million). 
Efficacy (absence of motility) is defined by comparison to positive control, milbemycin oxime, 
and a low concentration in ppm. 
 
Figure 15 comparises the efficacies of in vitro microfilarial tests and LDA. 
Overall microfilariae of D. immitis and A. viteae were less sensitive to AAD than the 
larvae of GI nematodes. However, the detection of compounds’ efficacy is more 
specific if microfilarial test is used to select compounds for the filarial in vivo test. 
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Figure 15. In vitro efficacies, EC 90, of AADs against gastro-intestinal nematodes in the 
LDA, from egg to L3 were evaluated after seven days of incubation. In vitro efficacies of 
AADs were evaluated against D. immitis and A. viteae microfilariae after 72 hours of 
incubation all tests were performed in triplicates. Results are represented in ppm (particle per 
million). Efficacy (absence of motility) is defined by comparison to positive control, 
milbemycin oxime, and a low concentration in ppm. 
 
In summary, AADs are active in vitro against microfilariae of D. immitis and of A. 
viteae. However, AADs so far did not show efficacy in vivo against D. immitis in dogs 
and A. viteae in gerbils (unpublished results).  
These results raise further questions. Why are AAD active against microfilariae in 
vitro? Presumably because they express MPTL-1-like targets. Why are they not 
active in vivo? Maybe because such targets are only expressed in the microfilarial 
stage, or because of pharmacokinetic problems.  
The appropriate method to get closer to the receptor is to learn more information 
about the genome of the heartworm. To follow this way, refer to the third chapter 
“The genome of the heartworm, Dirofilaria immitis”. 
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Chapter 3. The genome of the 
heartworm, Dirofilaria immitis 
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Abstract 
The heartworm Dirofilaria immitis is an important nematode parasite of dogs and other mammals, 
including humans. Transmitted by mosquitoes in warmer climatic zones, it is spreading across 
Southern Europe and the Americas at an alarming pace. There is no vaccine and chemotherapy is 
prone to complications. To learn more about this elusive parasite, we have sequenced the genomes 
of D. immitis and its endosymbiont Wolbachia using Illumina technology. In the 84.2 Mb of nuclear 
genomic assembly, we predict 10,179 protein coding genes, and 823 genes in the 0.9 Mb Wolbachia 
genome. The D. immitis genome harbors neither DNA transposons nor active retrotransposons, and 
there is extraordinarily little genetic variation between two sequenced isolates from Europe and the 
USA. Analysis of 990 orthologous genes resolves filarial nematode phylogeny, placing D. immitis next 
to Onchocerca species. Differential presence of anabolic pathways such as heme biosynthesis or 
purine de novo synthesis hints at the intricate relationship between the heartworm and Wolbachia. 
Comparing the D. immitis predicted proteome to other nematodes, and to mammalian hosts, 
identifies families of potential drug targets, immune modulators and vaccine candidates. The 
genome sequence will both support the development of new tools to combat dirofilariasis and aid 
efforts to control the related human filariases, which belong to the most neglected of all parasitoses. 
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Introduction 
The heartworm Dirofilaria immitis (Leidy, 1856) is an onchocercid parasitic nematode of mammals 
that is transmitted by various mosquitoes including Aedes, Anopheles and Culex spp. The definitive 
host is the dog, yet it also infects cats, foxes, coyotes, and even humans (1). Dirofilariasis of dogs is a 
severe and potentially fatal disease. Adult nematodes of 20 to 30 cm reside in the pulmonary 
arteries, and the initial damage is to the lung. The spectrum of subsequent pathologies related to 
chronic heartworm infection is broad, the most serious manifestation being heart failure. Recent 
rapid spread of D. immitis through the US and southern Europe (2,3) is being favored by multiple 
factors. Global warming is expanding the activity season of vector mosquitoes, increasing their 
abundance and the likelihood of transmission of the parasite, and there are growing numbers of 
pets, reservoir animals, and 'traveling' dogs (2,3). 
 D. immitis' lifecycle is typical for Onchocercidae: microfilariae, shed into the bloodstream by 
adult females, are ingested by a mosquito where they develop into L3 larvae and migrate to the 
labium. The prepatent period in the newly bitten dog is six to nine months, during which the injected 
larvae undergo two further molts and migrate via muscle fibers to the pulmonary vasculature, where 
the adult nematodes develop. Currently, diagnosis is based on the detection of circulating 
microfilariae or antigens from mature females, which is problematic in cats and humans. Treatment 
of dirofilariasis is problematic too, since the only adulticide approved by the FDA, the arsenical 
melarsomine dihydrochloride, can cause adverse neurological reactions. Treatment carries a 
significant risk of lethality, due to blockage of the pulmonary artery by dead nematodes. No vaccine 
is available. These issues, together with the alarming increasing spread of D. immitis, prompted the 
American Heartworm Society to recommend year-round chemoprophylactic treatment of all dogs 
(4), to kill the larval stages before they develop into adults. This requires monthly administration of 
anthelmintics, predominantly macrocyclic lactones such as ivermectin, milbemycin, or moxidectin. 
 D. immitis is closely related to human-pathogenic, onchocercid nematodes such as Brugia 
malayi and Wuchereria bancrofti, the etiological agents of lymphatic filariasis, and Loa loa and 
Onchocerca volvulus, which cause subcutaneous filariasis and river blindness. These disabling 
parasites are endemic in tropical and sub-tropical regions around the globe, with an estimated 380 
million people affected (5). Improved diagnostics, new drugs, and, ultimately, effective vaccines are 
sorely needed. The sequencing of the B. malayi genome provided insights into the molecular 
mechanisms of immune evasion and a rational basis for drug design (6). Onchocercid nematodes are 
commonly infected with Wolbachia, an alphaproteobacterial endosymbiont that is essential for the 
fecundity, development, and survival of the nematodes, and this is an additional source of potential 
drug targets (7-10). However, the human-pathogenic Onchocercidae does not represent an attractive 
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market for the pharmacological industry, as projected income would not cover costs for drug 
development. The heartworm may hold a possible solution to this dilemma: the market for novel 
canine anthelmintics is big, and the drug targets are likely to be conserved in human-pathogenic 
species, given their high phylogenetic relatedness. Thus the D. immitis genome is of interest for 
veterinary as well as human medicine. Here we present the draft genome sequences of D. immitis 
and its Wolbachia endosymbiont (wDi), and use these data to clarify its phylogenetic position among 
the Onchocercidae, investigate the relationships between nematode and endosymbiont, and identify 
new drug and vaccine targets. 
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Results 
Sequencing and genome assembly. Genomic DNA was isolated from single individuals of two D. 
immitis lines originally isolated from naturally infected dogs, one from Georgia (USA) and the other 
from Pavia (Italy). Several libraries of different insert sizes were constructed and sequenced on 
Illumina GA and HiSeq instruments. We also sequenced adult male and adult female transcriptomes 
from the Georgia nematodes using Illumina RNA-Seq. A total of 16 gigabase (Gb) of genomic 
sequence passed rigorous quality checks. As the D. immitis genome is likely to be the same size as 
related Onchocercidae (~95 mega bases [Mb]), this corresponds to ~170-fold coverage. We tested 
different assembly tools and parameters and chose ABySS (11) with a k-mer size of 35, as this 
performed best based on statistical and biological measures (see Table S2 for details). We filtered 
contigs mapping to the mitochondrial genome (12) and those with significant sequence similarity to 
Wolbachia genomes from B. malayi and arthropods. The final nuclear assembly, which was obtained 
after redundancy reduction with CD-Hit (13), contained 84.2 Mb of sequence in 31,291 contigs with 
an N50 of 10,584 bases (Table 1 and Table S1). We assembled a draft genome of the Wolbachia of D. 
immitis (wDi) by collecting all reads and their pairs mapping to Wolbachia-like contigs and 
reassembling them using tuned parameters in Velvet (14). The wDi genome assembled in 62 contigs 
spanning 902,182 bases with a contig N50 size of 23,251 bases. 
 
Lack of genetic diversity between the sequenced D. immitis isolates. Even though the two D. 
immitis samples were isolated 8,000 km apart, on two different continents, the raw data assembled 
well together. We tested genetic diversity between the strains by mapping the reads from each 
strain back to the draft assembly, and found only 32,729 high quality variations, a very low per-
nucleotide diversity rate of 0.04%. This hypodiversity is consistent with the hypothesis that the 
heartworm arrived in the New World with European immigrants (it was first described in the 
Americas 164 years ago (15)). Assuming one generation per year, the Italian and American isolates in 
our study would be a minimum of 328 generations apart, and the rate of genomic change ≈ 1.2 x 10-9 
per site per generation, comparable to the single-nucleotide mutation estimation rate of 3.5 x 10-9 
per site per generation found in Drosophila (16). 
 
A metazoan genome without active transposable elements. The D. immitis genome was surveyed 
for the three main classes of transposable elements (DNA transposons, LTR retrotransposons, and 
non-LTR retrotransposons). No traces of DNA transposons or non-LTR retrotransposons were found. 
However, a total of 376 fragments of BEL family PAO LTR retrotransposons (17) were identified. None 
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of these fragments were functional, as all contained frame shifts and stop codons in the coding 
sequence (Figure S1). These D. immitis PAO pseudogenes are most similar to PAO retrotransposons 
from B. malayi (6). Several of the B. malayi PAO retrotransposons are likely to be active, but B. 
malayi has a lower density of PAO elements and fragments overall (3.4 PAO per Mb, 8.3% of which 
are predicted to be active) compared to D. immitis (4.6 per Mb, none of which active). As far as we 
are aware, D. immitis is the first metazoan lacking active transposable elements. 
 
Prediction of genes and proteins. Three parallel strategies were followed to predict and validate 
protein-coding genes from the assembled D. immitis contigs: (i) prediction with the ab initio gene 
finders SNAP (18) and Augustus (19) using a B. malayi training set; (ii) direct alignment to B. malayi 
proteins; and (iii) alignment to an assembly of the RNA-Seq data. The three lines of evidence were 
integrated by the Maker annotation pipeline (20), resulting in 11,375 gene models, 897 of which 
possessed alternate transcripts. The total number of predicted proteins of length 100 amino acids or 
more was 10,179, which is similar to the 9,807 predicted for B. malayi (Table 1). Based on matches to 
D. immitis expressed sequence tags and core eukaryotic gene completeness (21), the D. immitis 
proteome is near-complete. Gene density is similar in D. immitis and B. malayi: in both about 18% of 
the genome is protein-coding (Table 1). This contrasts with C. elegans, which has about twice as 
many genes across 30% of its genome. We used this proteome prediction for a series of further 
analyses. 
 
Phylogeny of the Onchocercidae. The human-parasitic Onchocercidae have been grouped into two 
clades: Onchocerca species and the group Brugia/Wuchereria/Loa. To make best use of model 
species it is necessary to understand their relationships to the human targets. In addition to D. 
immitis, Litomosoides sigmodontis, a parasite of rodents, is increasingly used as a model for human 
disease (22). The relationships of these species to human-infective onchocercids has been poorly 
resolved (23,24). We assembled a dataset of 990 putatively orthologous genes using inParanoid (25) 
and QuickParanoid (http://pl.postech.ac.kr/QuickParanoid/) from the proteomes of D. immitis, B. 
malayi, Onchocerca ochengi (a cattle parasite closely related to human-infective O. volvulus), 
Litomosoides sigmodontis, L. loa, W. bancrofti, and, as an outgroup, the non-onchocercid spirurian 
Ascaris suum (26)(Figure S2). A Muscle-aligned (27) supermatrix was analyzed using RAxML (28), and 
a robustly supported tree derived (Figure 1). D. immitis is sister to O. ochengi , and the murine model 
L. sigmodontis is sister to the Brugia clade. D. immitis thus stands as a specific model for human and 
other onchocerciases. 
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The Wolbachia genome and its contribution to metabolism. The relationship between filarial 
nematode Wolbachia endosymbionts and their hosts has been the subject of intense scrutiny, as 
treatment of infected mammal hosts with tetracycline and other antibiotics results in clearance of 
the nematodes, suggesting a mutualistic symbiosis (23). The metabolic basis of this symbiosis 
remains unclear. It has been proposed that the Wolbachia endosymbiont of B. malayi (wBm) 
provides with additional sources of critical metabolites such as heme and riboflavin (29). We 
annotated the wDi genome using the RAST server (30), and interrogated these annotations to 
examine the symbiont's biochemical capabilities. C. elegans and other nematodes (including B. 
malayi, and, on the basis of the genome sequence presented here, D. immitis) are deficient in heme 
synthesis but wBm has an intact heme pathway (Figure S3) and a ccmB heme exporter suggesting it 
may support its host by providing heme. wBm has a complete pathway from succinyl-CoA to heme 
(one apparently missing component, hemG may be substituted by a functional hemY). wDi lacks both 
hemY and hemG (and the recently described hemJ that can perform the same transformation). This 
step in the heme pathway is apparently absent in other bacteria, and so this may not indicate a non-
functional heme synthesis pathway. Further anabolic pathways absent in D. immitis but present in 
wDi are purine and pyrimidine de novo synthesis. While D. immitis has but two enzymes, PRPP 
synthetase and adenylosuccinate lyase, wDi has the full complement of 10 enzymes required to 
synthesize inosine monophosphate (Figure S3). 
 wBm is deficient in folate synthesis, as it lacks dihydrofolate reductase and dihydroneopterin 
aldolase. wDi has both these genes, suggesting it can metabolize 7,8-dihydrofolate to folate and 
5,6,7,8-tetrahydrofolate, and utilize dihydroneopterin as an input to folate metabolism. Wolbachia 
wMel from Drosophila melanogaster has both these enzymes, and they are variably present in other 
alphaproteobacteria. Whether this pathway contributes to the nematode symbiosis is unclear, but it 
does highlight another component of Wolbachia metabolism that may be accessible to drug 
development. Further wDi gene products that might be exploited as drug targets include nucleic acid 
synthesis and cell division proteins such as FtsZ and DnaB, the fatty acid synthesis enzymes FabZ and 
AcpS, components of the Sec protein secretion system, and, possibly, the peptidoglycan synthesis 
enzymes of the Mur operon. All these are unique proteins in wDi, do not have counterparts in 
mammals, and are being developed as antibiotic drug targets for bacterial infections such as 
tuberculosis. 
 The wBm genome is rich in repeats, many associated with WO bacteriophage. We identified 
only one region of the wDi genome that has similarity to WO, spanning a widely conserved 
hypothetical protein of unknown function. wDi appears to be devoid of bacteriophage. As phage 
genes comprise 14% of the wBm genome (and 134 ORFs) this may explain the smaller genome size of 
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wDi. Genes with ankyrin repeats have been associated with parasitic phenotypes in Wolbachia of 
insects (31), and ankyrin repeat genes are found in phage segments. wDi also has 3 fewer ankyrin 
repeat containing proteins than wBm. 
 Horizontal gene transfer from Wolbachia to the nuclear genome is common in hosts 
harboring this endosymbiont (29), and it has been proposed that these transfers may confer new 
functionality to the nuclear genome, though this is unlikely (32). We identified 775 elements 
(spanning 170,324 bp) of over 100 bases with 80% identity or greater to wDi, but only 5 of these 
elements matched more than 90% of the length of a wDi ORF and were not interrupted by frame-
shifting indels or stop codons. Only one of these putative lateral gene transfers had a match to a 
known Wolbachia protein (tRNA pseudouridine synthase) but we found no evidence of transcription 
of this gene in our RNA-Seq data set and thus conclude that although elements from wDi have been 
inserted into the nuclear genome, as observed in other intracellular symbioses, none of them are 
likely to produce functional proteins. Frequency patterns of short palindromes can serve as a specific 
finger-print for DNA (33). We compared the presumed nuclear insertions, D. immitis genomic 
sequence, and wDi genomic sequence based on the actual occurrence of palindromes of length 4 in 
relation to their expected occurrence given the GC-content (Table 1) of the target sequences. The 
suspected DNA fragments clearly clustered with the Wolbachia genome (Figure S4), providing further 
evidence that they had been acquired by the nucleus through horizontal transfer. 
 
Existing drug targets of D. immitis. Many of the molecular targets of currently used anthelmintics 
were identified by forward genetics in the model nematode C. elegans (Table 2) (34): the macrocyclic 
lactones (ivermectin), benzimidazoles (albendazole), imidazothiazoles (levamisole), 
cyclodepsipeptides (emodepside), and the aminoacetonitrile derivatives (monepantel). Most 
prominent are neural membrane proteins, highlighting the importance of the neuromuscular 
junction as a hotspot of anthelmintic drug action. Two superfamilies of membrane proteins are 
among the prime targets of known pharmacophores and natural toxins: the G protein-coupled 
receptors (GPCR) and the ligand-gated ion channels (LGIC). LGIC are ionotropic receptors of 
acetylcholine, GABA, glutamate, or other neurotransmitters. GPCR are coupled to heterotrimeric G 
proteins and respond to a large variety of odors, pheromones, hormones, or neurotransmitters. The 
C. elegans genome encodes more members of these two families than any other animal. This is 
illustrated by the frequency distribution of predicted transmembrane domains (TM) per protein 
(Figure 2), where peaks of four and seven TM indicate LGICs and GPCRs, respectively. Such peaks are 
absent in the TM frequency distribution of D. immitis proteins (Figure 2). Another pharmacologically 
interesting family of transmembrane proteins apparently underrepresented in D. immitis compared 
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to C. elegans is the twelve TM domain ABC transporter family. ABC transporters carry out a multitude 
of active transport processes including drug efflux. 
 However, some proven drug targets appear to be missing from D. immitis. There are no 
members of the DEG-3 subfamily of acetylcholine receptors, which contains the presumed targets of 
monepantel (35). This contrasts with B. malayi, which has DEG-3 and DES-2 orthologues. The target 
space of levamisole and ivermectin in C. elegans comprises a large number of different LGIC, some of 
which do not have an orthologue in D. immitis (Table 2), indicating that those present are sufficient 
to confer drug susceptibility. Of the drugs listed in Table 2, flubendazole (36), mebendazole (37), 
levamisole (38), ivermectin, milbemycin, moxidectin, and selamectin (39,40) have been 
demonstrated to be active against D. immitis. 
 
New drug target candidates in D. immitis. New potential drug targets were identified in silico 
through an exclusion pipeline following previous schemes for anthelmintic drug discovery (41,42). 
Starting from the complete set of predicted D. immitis proteins, we applied the following inclusion 
criteria for candidate drug targets: (i) absence of an orthologue in the dog or human proteome, (ii) 
presence of a C. elegans orthologue that is essential for survival or development (based on RNAi 
phenotypes), (iii) absence of additional D. immitis paralogues and (iv) predicted function as an 
enzyme or receptor. Among the 20 identified candidates (Table 3) are several proven drug targets, 
such as RNA-dependent RNA polymerase (antiviral), apurinic/apyrimidinic endonuclease and 
hedgehog proteins (anticancer), UDP-galactopyranose mutase (antimycobacterial), sterol-C24-
methyltransferase (antifungal), and the insecticide targets chitin synthase. The identified D. immitis 
orthologues of these enzymes might serve as the starting points for the development of new 
anthelmintics. 
 
Immune modulators and vaccine candidates. Filarial nematodes modulate the immune systems of 
their hosts in complex ways that result in an apparently intact immune system that ignores a large 
parasite residing, sometimes for decades, in tissues or the bloodstream. They also require intact 
immune systems to develop properly (43). Often, immune responses result in pathology for the host 
in addition to parasite clearance, and Wolbachia may exacerbate these responses (44). Strategies for 
development of a vaccine against filariases thus depend on delivering the correct antigens to the 
right arm of the immune system, avoiding induction of dangerous responses, and deflecting or 
stopping immune suppression by the parasite. We surveyed the D. immitis genome for molecules 
currently proposed as vaccine candidates in other onchocercids (45,46), and identified homologues 
for all fourteen classes of molecules (Table 4). 
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 The mechanisms of immune modulation by onchocercid nematodes remain enigmatic, but 
involvement of proteases and protease inhibitors (such as leucyl aminopeptidase (LAP), serpins and 
cyctatins), homologues of ancient immune system signalling molecules (such as transforming growth 
factor beta [TGFb] and macrophage migration inhibition factor [MIF]), and possible mimics of 
immune molecules have all been proposed. In D. immitis, we identified LAP, three cystatins, many 
serpins, two MIF genes, orthologous to the MIF-1 and MIF-2 genes of B. malayi and O. volvulus, and 
four TGFb homologues (Table 4). We also identified a homologue of suppressor of cytokine signalling 
5 (SOCS5). SOCS proteins consist of a central SH2 domain, a C-terminal SOCS box, and a variable N-
terminal domain. SOCS5 negatively regulates the JAK/STAT pathway and inhibits the IL-4 pathway in 
T helper cells, promoting TH1 differentiation (47). The SH2 domain recognizes target proteins and the 
SOCS box recruits an ubiquitin complex that mediates proteosomal degradation of the target. SOCS5 
homologues can be identified in animal-parasitic nematodes, including B. malayi, D. immitis, L. loa, A. 
suum and Trichinella spiralis, but SOCS5 is absent from the free-living C. elegans, the necromenic 
Pristionchus pacificus, and the plant parasitic Meloidogyne spp. Several viruses induce host SOCS 
protein expression for immune evasion and survival (48). D. immitis and other filarial nematodes (49) 
may use SOCS5 homologues to mimic host SOCS5. We also identified a homologue of IL16, a PDZ-
domain containing, pleiotropic cytokine (50). In mammals IL16 acts via the CD4 receptor to modulate 
the activity of a wide range of immune effector cells, including T-cells and dendritic cells (51). Again, 
this molecule is only present in parasitic nematodes (including A. suum (26)) and absent from free-
living and plant-parasitic species' genomes. We suggest that these molecules, and perhaps other 
mimics of cytokines and modulators, are the effector toolkit used by filarial nematodes to build an 
immunologically compromised niche. 
 In parasitic nematodes, secreted proteins have been found to be more rapidly evolving than 
other classes (52), and are thus likely to harbor novelties associated with host manipulation and 
invasion. The D. immitis proteome was divided into transmembrane (n = 1416; presence of TM 
domains (53)), secreted (638; N-terminal export signals (53)), GPI anchored (151; C-terminal GPI 
anchor attachment signals (54)) and cytosolic (8133; all remaining), sets. Each protein was aligned to 
its best match from B. malayi and mean alignment scores compared between sets. Secreted and GPI 
anchored proteins had significantly lower alignment scores  (p<0.01; 1-way Anova followed by 
Kruskal-Wallis' post test) than the cytosolic or transmembrane proteins (Figure S2), indicating that 
the divergence between the two parasites is more pronounced in proteins potentially exposed to the 
host. 
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Discussion 
The D. immitis genome sequence described here is only the second to be determined for an 
onchocercid nematode, despite the social and economic importance of these parasites. We used 
solely short-read Illumina technology, and the high throughput of this platform allowed us to use 
stringent quality-filtering and assembly metrics to derive a good draft genome. Three genomes were 
co-sequenced: the mitochondrial (at about 4000-fold read coverage; this was determined previously 
(12)), the Wolbachia symbiont wDi (about 1000-fold coverage of the 0.9 Mb genome) and the 
nuclear genome (about 150-fold coverage). After redundancy reduction the total size of the nuclear 
assembly was 84.2 Mb, slightly smaller than the 93.6 Mb published for B. malayi (6). Two 
peculiarities of the assembled D. immitis genome are striking: the apparent genetic homogeneity and 
the lack of active transposable elements. The lack of heterogeneity was convenient in that it allowed 
us to pool data obtained from two different D. immitis isolates, one from Pavia, Italy, and the other 
from Georgia, USA. Polymorphisms called from the independent sequencing of the two isolates 
yielded a per-nucleotide diversity of 0.04%. Startling as this hypovariability may be, it is in agreement 
with microsatellite population genetics (55) and with the hypothesis that the heartworm arrived in 
the New World only recently with European immigrants (15). The first report of dirofilariasis in the 
US dates from 1847, as opposed to a 1626 observation from Italy. Both our nematodes fall within the 
single USA population defined by microsatellite analyses (55). The lack of genetic diversity in the 
nuclear genome will make identification of mutations conferring drug resistance much easier. The 
lack of DNA transposons and active retrotransposons in D. immitis is a strong negative result since 
potentially active elements are relatively easy to identify (they are present in multiple, highly similar 
copies). To our knowledge, this is the first metazoan genome devoid of active transposable elements. 
 The Wolbachia wDi genome, with 823 predicted proteins, complements the D. immitis 
nuclear genome in that it encodes enzymes for anabolic pathways which are missing in the latter, 
e.g. heme biosynthesis and purine de novo synthesis (Figure S3). In contrast to wBm, wDi also carries 
the genes for folate synthesis, suggesting that folate too might be supplied by the endosymbiont. 
However, folate, purines, or heme could also be taken up from the mammalian or insect host, and so 
it remains to be shown whether such metabolites are actually delivered from wDi to D. immitis. In 
any case the endosymbiont, being essential for proliferation of D. immitis, represents a target for 
control of the heartworm. Screening the predicted wDi proteome returned expected antibiotic drug 
targets such as Fts and Sec proteins, but also the products of the Mur operon required for 
peptidoglycan synthesis. The role of peptidoglycan in the obligate intracellular Wolbachia remains to 
be elucidated. 
 All the anthelmintics used in human medicine were originally developed for the veterinary 
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sector. We have pursued two approaches to identify potential drug targets in D. immitis: top-down, 
starting with the known anthelmintic targets of C. elegans (Table 2), and bottom-up, narrowing down 
the predicted D. immitis proteome to a list of essential, unique, and druggable targets (Table 3). 
While the majority of the current anthelmintics activate their target (thereby interfering with 
synaptic signal transduction), the second approach aimed to identify inhibitable targets. The applied 
criteria – presence of an essential orthologue in C. elegans, absence of any significantly similar 
protein in human or dog, and absence of paralogues in D. immitis – are obviously also excluding 
suitable targets such as novel and filaria-specific proteins (see Figure 1). Our goal was to end up with 
a manageable, rather than complete, list of unique D. immitis proteins that are likely to be essential 
and druggable. Some of the candidates identified are worth further investigation based on their 
presumed role in signal transduction, e.g. the nematode-specific GPCRs or hedgehog proteins (Table 
3). Others have already been validated as drug targets in other systems: sterol-C24-
methyltransferase (EC 2.1.1.41) is a target of sinefungin, chitin synthase (2.4.1.16) is the target of the 
insecticide lufenuron, and the mannosyltransferase bre-3 is required for interaction of Bacillus 
thuringiensis toxin with intestinal cells (56). The discovery of new D. immitis drug targets would be 
timely since resistance to macrocyclic lactones has recently been reported from the Southern USA 
(57,58). 
 Two common properties of filarid parasites are (i) a fascinating biology involving immune 
evasion, arthropod vectors and Wolbachia endosymbionts, and (ii) a pressing need for new drugs, 
improved diagnostics and – ideally – vaccines. We hope that the genome sequence of D. immitis 
presented here will contribute to an increased understanding and to new leads for control and 
eradication. 
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Materials and Methods 
Dirofilaria immitis isolates and maintenance. The D. immitis Pavia isolate is an inbred strain 
originally isolated in a veterinary practice in northern Italy. Adult nematodes were recovered after 
necropsy of infected dogs (permit number FR401e/08 from the Veterinary Office Canton de Fribourg) 
that were the control group of on-going investigations and not sacrificed for the sake of the present 
study. The nematodes were extracted from the dogs’ right pulmonary artery and from the heart. 
Adult heartworms were immediately sexed, counted, measured, and washed in Hank’s Balanced Salt 
Solution (Gibco) supplemented with streptomycin/penicillin (Invitrogen) and fungizone/amphotericin 
(Invitrogen). Individual nematodes were snap-frozen in liquid nitrogen and cryopreserved at -80°C. 
 
Isolation of nucleic acids and sample preparation. To extract genomic DNA from individual 
heartworms, segments of approximately 2 cm were ground under liquid nitrogen with a micropestle, 
incubated at 56°C for three hours in lysis buffer supplemented with 100 mg/ml RNase A (QIAamp 
DNA extraction kit, Qiagen), and further processed following the supplier's protocol. The DNA was 
washed three times before elution. DNA quality and quantity were assessed by electrophoresis in 
1.5% agarose gels (agarose LE analytic grade, Promega) supplemented with Sybr safe DNA stain 
(Invitrogen), and by measuring absorbance (Nanodrop 2000c, Thermo Scientific) or fluorescence 
(Qubit, Invitrogen). RNA was extracted from the nematodes using the protocol described in the 
Qiagen miRNeasy Mini Handbook October 2007. Poly-A containing mRNA molecules were purified 
using poly-T oligo-attached magnetic beads. Following purification, the mRNA was fragmented into 
small pieces using divalent cations under elevated temperature. Cleaved RNA fragments were then 
copied into first strand cDNA using reverse transcriptase and a high concentration of random 
hexamer primers. This was followed by second strand cDNA synthesis using DNA Polymerase I and 
RNaseH. 
 
Sequence generation and assembly. Whole genome shotgun sequences were generated at the 
GenePool (University of Edinburgh) and at Fasteris SA (Geneva, Switzerland) using Illumina GA-IIx and 
HiSeq 2000 instruments. In addition to standard short-insert (100-400 bp) paired end libraries, long-
insert (3-4 kb) libraries were also attempted and used as described below. Sequences were 
basecalled using the Illumina CASAVA pipeline. Four libraries (Table S1) were used in the final 
assembly totalling 28 Gb in 295 M reads, and have been deposited in the EBI Short Read Archive with 
accession ID ERA032353. We trimmed low quality reads aggressively as we estimated we had more 
than 200 fold coverage. Low quality bases were trimmed from the 3’ end of all reads if they were 
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below a Phred quality equivalent of 20 using FASTQ Quality Trimmer. Reads containing uncalled 
bases (‘N’s) and reads shorter than 35 bases after trimming were discarded along with their pairs. 
The long-insert mate-pair reads were used as single-ended sequences in the release candidate 
assembly because the proportion of paired-end contamination was deemed excessive. In addition, 
the reads in this library were truncated at 50 bases to minimise the likelihood of chimeric joins as a 
result of reads spanning the junction point of the circularised long-insert fragments, leaving a total of 
16 Gb in 271 M reads across all 4 libraries. The reads were assembled into contiguous sequences and 
scaffolded using ABySS after evaluating a range of values for the k-mer size (k) and the minimum 
number of pairs connecting 2 contigs (n). We also tested Velvet and CLC-bio with a range of 
parameters but chose ABySS with k=35 and n=4 based on primary observations such as N50 value, 
maximum contig length, total number of bases in contigs, total number of Ns in contigs (all evaluated 
for a minimum contig length of 200 bp and 1000 bp), as well as a suite of biological completeness 
tests described below (Table S2). 
 
D. immitis mitochondrion. All contigs in the best ABySS assembly were screened for mitochondrial 
contigs using the published D. immitis mitochondrial genome. 
 
Wolbachia genome assembly. We screened our best ABySS assembly for known Wolbachia DNA 
using BLAST against complete Wolbachia genomes from EMBL/GenBank/DDBJ. To obtain a more 
accurate assembly of the Wolbachia of D. immitis (wDi) genome, we extracted all the read pairs 
where at least one read mapped to any likely Wolbachia contig, and reassembled these 6,912,659 
read pairs using more accurate k-mer and coverage parameters with Velvet version 1.1.03 (k-mer 
size 45, expected k-mer coverage 400, k-mer coverage cutoff 150). The assembly was checked for 
numerical and biological optimality as outlined above. Although not a finished genome, we believe 
this draft is essentially complete because a MEGABLAST search of 107 existing genome survey 
sequences (GSS) from wDi on GenBank (Accession numbers ET041559 - ET041665) found 106 of 
them in our wDi assembly at an e-value of 1e-50.  
 
Assembly evaluation and final assembly freeze. For each assembly generated using different 
programs and varying parameters, we tallied a series of contig size metrics as well as biological 
metrics such as alignments to known EST sequences, genes predicted, and CEGMA completeness. 
4005 D. immitis EST sequences were obtained from NCBI dbEST and assembled into 1810 contigs 
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using PHRAP. BLASTn was used to determine how many of these longer transcripts were found in the 
candidate assembly. A transcript was deemed reasonably complete if 80% of its length was found in 
BLASTn matches and the number of fragmented (i.e. on different contigs) and unfragmented hits 
were counted. Augustus was used to predict the number of genes and total exon length for each 
assembly using the HMM for Brugia malayi. Table S2 shows the results of these metrics, and the 
ABySS assembly with k=35, n=4 was chosen for further processing. To obtain the D. immitis nuclear 
genome, we screened the contig set for D. immitis mitochondrial sequence (GenBank ID AJ537512) 
and for Wolbachia sequences (GenBank IDs AM999887, CP001391, AE017321, and AE017196, and 
our re-assembled Wolbachia genome). We also reduced contig redundancy by using the program CD-
HIT-EST to cluster those contigs that were at least 97% identical. This reduced contig set was frozen 
for all further analyses in this paper. 
 
Comparing Wolbachia of D. immitis and B. malayi. Comparing the wDi genome to that of wBm using 
PROmer revealed significant breakage of synteny between the two genomes. Repeats in the 
Wolbachia of D. immitis (wDi) and Wolbachia of B. malayi (wBm) genomes were determined using 
self against self NUCMER (with –maxmatch parameter). The wDi draft genome was compared to the 
Wolbachia of B. malayi (wBm), the most closely related sequenced Wolbachia genome sequence 
available (GenBank ID: NC_006833). The wDi genome was as much as 16% smaller than the 
1,080,084 bp wBm genome. One reason for the smaller genome size is that wDi had been assembled 
using Velvet, a de-Bruijn graph assembler that collapsed repeated regions into single contigs. As a 
result, only one 89 bp repeat was found in the wDi assembly compared to 49 repeats in wBm ranging 
in size from 226 to 3082 bp.  
 
RNAseq assembly. We created a transcriptional profile of D. immitis by generating RNAseq libraries 
from an adult male and an adult female, and sequenced a total of 11,019,886 (male) and 21,643,293 
(female) read pairs of length 54 bases each on the Illumina GAIIx platform (ArrayExpress accession: E-
MTAB-714; ENA study accession: ERP000758). The ends of these reads were trimmed if they were 
low quality (below an equivalent Phred score of 20) and the resulting 31,396,183 read pairs were 
assembled using Trans-ABySS with k-mer values from 23 to 47 in steps of 4. We also tried using Oases 
to assemble the transcriptome, and although the resulting transcripts were slightly longer, they had 
lower CEGMA completeness values and aligned less well to the set of 1810 D. immitis EST contigs and 
B. malayi peptides that we used in our genome assembly evaluation (Table S3). 
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Gene prediction and annotation. The MAKER annotation pipeline was used for a first pass automatic 
annotation of the assembly freeze. The pipeline first masked repeats using RepeatMasker 3.2.9, 
searching for all "Nematoda" repeats, with RepBase libraries for RepeatMasker version 20110419. 
MAKER predicted genes using evidence from several sources: (a) EST alignments from D. immitis 
(RNAseq assembly); (b) Protein alignments from Brugia malayi (WormBase release WS220); (c) Gene 
predictions from the ab-initio gene finders SNAP and Augustus, using the shipped HMM profiles for 
B. malayi. MAKER predicted 11,895 gene models that resulted in a total of 12,872 transcripts and 
peptides. Selected pathways were annotated with HMMer. For this purpose, all entries for a given 
E.C. number were downloaded from the manually curated section (SwissProt) of UniProt, 
redundancy reduced over a threshold of 90% identity, and aligned with ClustalW. Profiles were 
generated and searched against the D. immitis predicted proteome with HMMer 3.0. 
 
Prediction of TM domains and membrane proteins. Transmembrane domains were predicted with 
Phobius. Ligand-gated ion channels were predicted with PFAM profiles PF02931 (neurotransmitter-
gated ion-channel ligand binding domain) and PF02932 (neurotransmitter-gated ion-channel 
transmembrane region), considering only proteins that scored for both profiles. Similarly, proteins 
were annotated as ABC transporters if they scored for both PF00664 (ABC transporter 
transmembrane region) and PF00005 (ABC transporter, ATP-binding cassette). Putative G protein-
coupled receptors were identified with a HMM library consisting of PF00001, PF00002, PF00003, 
PF02949, PF08395, PF10292, PF02117, PF10316, PF10320, PF10322, PF10323, PF10324, PF10325, 
PF10326, and PF02116.   
 
Phylogenetics. Proteins for Ascaris suum were downloaded from EMBL-EBI  (http://www.ebi.ac.uk/), 
transcripts for Loa loa and Wuchereria bancrofti from the Broad Institute 
(http://www.broadinstitute.org/), and the transcriptome of Brugia malayi (version WS220) from 
Wormbase (ftp://ftp.wormbase.org/pub/wormbase/). Protein predictions for Litomosoides 
sigmodontis and Onchocerca ochengi were obtained from genome sequence projects at the Blaxter 
Lab. Finally, the protein predictions for Dirofilaria immitis were added to create a dataset of 7 species 
and 103,849 proteins. Orthology groups were constructed with inParanoid and QuickParanoid. 990 
clusters that shared one gene per species were identified, and the amino acid sequences for each 
cluster were aligned using Muscle. The nucleotide sequences were aligned based on the 
corresponding protein alignments with the program tranalign of the EMBOSS package. Maximum 
likelihood analysis was performed with RAxML 7.2.8, with a GTR+ (generalised time-reversible) 
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model, where base frequencies and gamma shape distribution were estimated from the data. The 
support values generated from RAxML using identical settings for 100 bootstrap replicates were 100 
for all branches. 
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Summary of software used. The following programs were used (or at least tested) for genome 
assembly, analysis, and annotation. 
 
Program / Resource Reference 
ABySS 1.2.0 Robertson et al. (2010) Nat Methods 7, 909-912 
Augustus 2.5.5 Stanke & Morgenstern (2005) Nuc Acids Res 33, W465-467 
BLAST Altschul et al. (1990) J Mol Biol 215, 403-410 
CASAVA 1.5 www.illumina.com/software/genome_analyzer_software.ilmn#casava 
CD-HIT Huang et al. (2010) Bioinformatics 26, 680-682 
CEGMA Parra et al. (2007) Bioinformatics 23, 1061-1067 
ClustalW Thompson et al. (1994) Nuc Acids Res 22, 4673-4680 
EMBOSS 6.3.1 Rice et al. (2000) Trends Genet 16: 276-277 
FASTQ Quality Trimmer hannonlab.cshl.edu/fastx_toolkit/ 
HMMer 3.0 Eddy SR (1995) Proc Int Conf Intell Syst Mol Biol 3, 114-120 
MAKER 2.08 Cantarel et al. (2008) Genome Res 18, 188-196 
Muscle 3.8.31 Edgar (2004) Nuc Acids Res 32: 1792-1797 
NUCMER Kurtz et al. (2004) Genome Biol 5: R12 
Phobius Käll et al. (2004) J Mol Biol 338: 1027-36 
QuickParanoid Ostlund et al. (2010) Nuc Acids Res 38, D196-203 
RAxML 7.2.8 Stamatakis et al. (2005) Bioinformatics 21, 456-463 
RepeatMasker 3.2.9 Chen N (2004) Curr Prot Bioinf, Chapter 4, Unit 4 10 
RepBase Kapitonov & Jurka (2008) Nature Rev Gen 9, 411-412; author reply 414 
SNAP Korf I (2004) BMC Bioinf 5, 59 
Velvet 1.1.0.3 Zerbino & Birney (2008) Genome Res 18: 821-829 
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Figure legends 
 
 
Figure 1. Phylogeny of the Onchocercidae. Phylogenetic consensus tree constructed from a set of 
990 genes that are present as single-copy in all available genome drafts from Onchocercidae and, as 
an outgroup, Ascaris suum. Icons represent the vectors and definite hosts. The bootstrap support 
was 100% for each node.  
 
 
Figure 2. Frequency distribution of predicted transmembrane domains. Transmembrane (TM) 
domains were predicted with Phobius for all proteins of C. elegans (grey) and D. immitis (red). In 
parallel, ligand-gated ion channels (LGIC, 4 TM domains per monomer), G protein coupled receptors 
(GPCR, 7 TM domains) and ATP-binding cassette transporters (ABC, 12 TM domains per transporter) 
were identified with hidden Markov model-based profiles from Pfam (see supplementary Methods); 
the number of obtained hits is plotted below the graph. 
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Tables 
 
 C. elegans B. malayi D. immitis 
Estimated genome size 100 Mb 95 Mb 95 Mb 
Assembly size 100 Mb 70,8 Mb 84,2 Mb 
Gene models 21,193 11,515 11,375 
Genes per Mb 235 162 135 
Number of predicted proteins 19’762 11’508 12,344 
Percent-protein-coding sequence 30.2 17.8 18.0 
Median number of exons per gene 6 5 5 
Median exon size 147 b 140 b 142 b 
Median intron size 68 b 219 b 226 b 
Overall GC content 35.4% 30.5% 28.3% 
Exons GC content 42.9% 39.6% 37.4% 
Introns GC content 29.1% 27.6% 26.6% 
 
Table 1. Genome metrics. Comparison of the genome assemblies of C. elegans, B. malayi and D. 
immitis. 
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Chemical class Drugs Target C. elegans  D. immitis 
Benzimidazole Albendazole 
Flubendazole 
Mebendazole 
 
Beta-tubulin BEN-1 DimmContig2035_DIMM36740 
Imidazothiazole Levamisole nACh receptor LEV-1 
LEV-8 
UNC-29 
UNC-38 
UNC-63 
 
- 
- 
DimmContig1332_DIMM30000 
DimmContig3506_DIMM45965 
DimmContig160_DIMM08405 
Macrocyclic 
lactone 
Ivermectin 
Milbemycin 
Moxidectin 
Selamectin 
Glutamate 
receptor 
AVR-14 
AVR-15 
GLC-1 
GLC-2 
 
GLC-3 
GLC-4 
 
DimmContig464_DIMM16610 
- 
- 
DimmContig953_DIMM25280, 
DimmContig692_DIMM21120 
- 
DimmContig747_DIMM22030 
  GABA receptor EXP-1 
GAB-1 
UNC-49 
 
DimmContig8852_DIMM57890- 
DimmContig1631_DIMM33210 
Cyclodepsipeptide Emodepside K
+
 channel SLO-1 
 
DimmContig1682_DIMM33710 
  Latrophilin GPCR LAT-1 
 
LAT-2 
 
DimmContig2098_DIMM37270, 
DimmContig2098_DIMM37275 
DimmContig514_DIMM17690 
Aminoacetonitrile 
derivative 
Monepantel nACh receptor ACR-23 
DES-2 
- 
- 
 
Table 2. Candidate drug targets, top-down search. Current anthelmintics, their known targets in C. 
elegans, and orthologues in D. immitis as identified with reciprocal BLAST searches using InParanoid. 
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D. immitis protein Predicted function H. sapiens 
log10 (E) 
C. lupus 
log10 (E) 
C. elegans 
RNAi 
Nucleic acid synthesis and repair 
DimmContig1353_DIMM30225 RNA-dependent RNA polymerase >1 0.89 lethal 
DimmContig188_DIMM09370 RNA-dependent RNA polymerase 0.28 0.11 lethal 
DimmContig829_DIMM23395 Apurinic/apyrimidinic endonuclease >1 -0.12 lethal 
Glycosylation and sugar metabolism 
DimmContig417_DIMM15580 dTDP-4-dehydrorhamnose 3,5-
epimerase 
0.23 0.04 lethal 
DimmContig51_DIMM03355 Beta-1,4-mannosyltransferase 0.95 0.94 lethal 
DimmContig3217_DIMM44525 UDP-galactopyranose mutase 0.36 0.08 molt 
defective 
DimmContig2055_DIMM36945 Chitin synthase -3.52 -4.00 lethal 
Lipid metabolism     
DimmContig5517_DIMM52545 Lipase 0.08 -1.60 lethal 
DimmContig338_DIMM13730 Sterol-C24-methyltransferase (Erg11) -3.10 -4.00 lethal 
DimmContig1280_DIMM28375 Methyltransferase -0.03 -0.15 lethal 
Transport     
DimmContig689_DIMM21065 Aquaporin -2.05 -0.52 lethal 
Signal transduction     
DimmContig333_DIMM13570 Nuclear hormone receptor -2.40 -4.52 lethal 
DimmContig245_DIMM11130 G-protein coupled receptor -1.06 -0.59 lethal 
DimmContig1550_DIMM32415 G-protein coupled receptor -1.26 -1.57 lethal 
DimmContig2384_DIMM39455 G-protein coupled receptor -2.70 -1.96 lethal 
DimmContig335_DIMM13630 Groundhog protein >1 0.04 lethal 
DimmContig3787_DIMM47150 Warthog  protein >1 0.78 lethal 
DimmContig48_DIMM03220 Warthog  protein >1 0.32 lethal 
DimmContig253_DIMM11410 Haloacid dehalogenase-like hydrolase -3.22 -4.00 lethal 
DimmContig326_DIMM13420 Apoptosis regulator ced-9 0.77 -1.02 lethal 
 
Table 3. Candidate drug targets, bottom-up search. Potential drug targets were filtered from the 
predicted D. immitis proteome using the following criteria: (i) presence of an orthologue in C. elegans 
which has as an RNAi phenotype lethal, L3_arrest, or molt_defective; (ii) absence of a significant 
BLAST match (E-value below 10-5) in the predicted proteomes of H. sapiens and C. lupus familiaris, 
and (iii) predicted function as an enzyme or receptor. 
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D. immitis 
protein(s) 
B. malayi 
orthologue(s) 
Description VC IM 
DIMM39040; 
DIMM39045  
BM18548 Pi-class glutathione S-transferase (GSTP) X  
DIMM29150 BM02625 Tropomyosin (TMY) X  
DIMM29270 BM00759; 
BM19824 
Fatty acid and retinoic acid binding protein (FAR) X  
DIMM47055 BM03010 Fructose bisphosphate aldolase (FBA) X  
DIMM59360  Astacin metalloprotease MP1 X  
DIMM37935; 
DIMM46475 
BM01859; 
BM09541; 
BM14520 
Chitinases (CHI) X  
DIMM48695 BM21967; 
BM08119 
Abundant larval transcript 1 (ALT-1; also known as SLAP) X  
DIMM48700 BM20051 "RAL-2"; unknown function; DUF148 superfamily (also known as SXP-1) X  
DIMM62215; 
DIMM45570; 
DIMM58880  
BM03177; 
BM05783; 
BM16294 
Activation associated proteins (ASP, also known as venom allergen 
homologues, VAH) 
X  
DIMM58690 BM02480 "OV103" Onchocerca vaccine candidate of unknown function X  
DIMM12355 BM07484; 
BM22082 
"B8" Onchocerca vaccine candidate of unknown function X  
DIMM55190; 
DIMM50565; 
DIMM48395 
BM00175; 
BM14240; 
BM04930; 
BM07956 
"B20" Onchocerca vaccine candidate of unknown function X  
DIMM56580 BM05118 Cysteine proteinase inhibitor 2 (CPI-2) X X 
DIMM18905 BM04900 Cysteine proteinase inhibitor 3 (CPI-3) X X 
DIMM11425 BM21284 Interleukin-16 (IL16)  X 
DIMM57180 BM00325 Leucyl aminopeptidase (LAP)  X 
DIMM28945 BM06847 Suppressor of cytokine signaling 5 (SOCS5)  X 
DIMM42430 BM07480 Macrophage migration inhibitory factor (MIF-1)  X 
DIMM40455 BM16561 Macrophage migration inhibitory factor 2 (MIF-2)  X 
DIMM23225 BM17713 Transforming growth factor beta (TGF) homologue of C. elegans TIG-2  X 
DIMM37585 BM20852 TGF homologue of C. elegans DAF-7  X 
DIMM29335 BM21753 TGF homologue of C. elegans DBL-1/CET-1  X 
DIMM61250 BM18112 TGF homologue of C. elegans UNC-129  X 
 
Table 4. Potential immune modulators and vaccine candidates. D. immitis proteins that are 
potential immune modulators (IM) or that have been proposed as vaccine candidates (VC) in other 
Onchocercidae. 
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Supplementary tables 
Library name fas1 fas2  blx mp 
Type 76 bp paired-end 76 bp paired-end 101 bp paired-end 100 bp mate-
paired 
Insert length 343 (58) 342 (57) 108 (16) - 
#Reads (raw) 23,527,084 35,637,504 47,085,106 188,325,900 
#Bases (raw) 1,788,058,384 2,708,450,304 4,755,595,706 18,832,590,000 
#Reads (trimmed) 15,725,202 28,369,128 45,328,600 181,344,222 
#Bases (trimmed) 1,083,296,217 2,006,850,353 4,446,959,717 9,049,499,979 
 
Table S1. Sequencing libraries. Counts of raw and quality-trimmed genome sequencing reads. Insert 
length is given as the median with standard deviation in parentheses. 
 
 ABySS Velvet 
Parameters Kmer 35 
using mp library as se, n=4 
Kmer 35 
se, -exp_cov auto -cov_cutoff auto 
Max contig size 167,771 117,878 
Number of contigs >=200 31,979 31,982 
Number of bases for contigs >=200 87,011,407 76,294,902 
GC for contigs >=200 28.3 28.8 
N50 for contigs >=200 10,474 7,125 
D.immitis ESTs recovered 1,533 1,442 
CEGMA completeness Complete 95% 
Partial 96% 
Complete 89% 
Partial 93% 
 
Table S2. Genome assembly comparisons. Based on the above data, the ABySS assembly was 
selected for all further analyses. 
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Assembler TransABySS Velvet-Oases 
Parameters Kmer range 23-47 Kmer 35, insert length 120 
Max. contig size 14,946 10,465 
Number of contigs >=300 bp 31,643 27,935 
Total bases in contigs >=300 bp 34,603,394 34,479,062 
N50 of contigs >=300 bp 1,477 1,702 
Mean length of contigs >=300 bp 1,094 1,234 
Number of contigs >=1000 bp 12,391 12,844 
Total bases in contigs >=1000 bp 23,720,523 25,873,800 
Alignments to sanger ESTs 
(>80% of EST covered) 
1,030 991 
CEGMA completeness Complete 94% 
Partial 96% 
Complete 88% 
Partial 93% 
B. malayi peptide blastx 
(>80% of ref. sequence covered) 
13,487 12,719 
 
Table S3. Transcriptome assembly comparisons. Based on the above data, the TransABySS assembly 
was selected for all further analyses. 
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Supplementary figures 
 
Figure S1. Example of a D. immitis PAO pseudogene. Panel A shows the 3 translation frames of the 
D. immitis PAO-290022 element (top), with the ATG and stop codons indicated by short and long 
vertical bars, respectively. The 5’ extremity of this transposable element is truncated. The horizontal 
red lines correspond the coding sequence matching the B. malayi PAO elements. This coding 
sequence contains 15 frame shifts and numerous stop codons. Below is a “reconstituted” version of 
the PAO-290022 coding sequence, where all the frame shifts have been removed manually. This 
artificial gene still contains 15 stop codons. Panel B is an alignment of the reconstituted protein 
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encoded by PAO-290022 (first lane: 1170 aa) and one full-length (and likely functional) B. malayi PAO 
element (second lane: EDP32991 - 1836 aa). 
 
Figure S2. Protein orthology groups. Numbers of proteins in different intersects of the predicted 
proteomes of filaria (Dirofilaria immitis, Brugia malayi, Onchocerca ochengi, Litomosoides 
sigmodontis, Loa loa, Wuchereria bancrofti) and Ascaris suum, as classified by InParanoid. Of the 
omnipresent orthology groups (blue sector), 990 had a single member in all the seven species and 
were therefore used to build the phylogenetic tree shown in Figure 1. 
 
Figure S3. GPI-anchored and secreted proteins are the least conserved. The D. immitis proteome 
was subdivided into the four classes 'cytosolic', 'transmembrane', 'secreted', and 'GPI anchored' 
based on the predicted presence of transmembrane domains, N-terminal export signals, and C-
terminal GPI anchor attachment signals as indicated (nc, not considered). For each set, every protein 
was aligned to its best match from B. malayi. Given that the defined classes of proteins differed in 
their median length, the Needleman-Wunsch global alignment algorithm was implemented (rather 
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than the local alignment performed by Blast) to avoid disfavoring of shorter proteins. The resultant 
scores were significantly lower for the secreted and GPI-anchored proteins as compared to 
transmembrane or cytosolic proteins (p<0.01; 1-way Anova followed by Kruskal-Wallis' post test). 
 
Figure S4. Anabolic pathways in Wolbachia and Dirofilaria. Three pathways of interest are shown. 
Hidden Markov model-based profiles were made for all enzymes involved and used to screen 
predicted proteomes with HMMer. The heat plot represents the best score obtained against each 
proteome. These scores were clustered by city block distance between the pathway 'vectors'. 
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Figure S5. Clustering of DNA based on palindrome frequency. Nuclear genomic DNA sequences of D. 
immitis (this work) and B. malayi (GenBank accession DS239371) were compared to Wolbachia wDi 
(this work) and wBm (NC_006833), mitochondria mDi (NC_005305) and mBm (NC_004298), and to 
joined DNA fragments ('horizontal transfer joined') suspected to have been horizontally transferred 
from wDi to the D. immitis nucleus (see main text). For each sequence string, the actual occurrence 
of the 16 possible palindromes of length 4 (top labels) was divided by the expected occurrence given 
its GC-content. These ratios were transformed to log2 and clustered based on city-block distance. The 
suspected DNA fragments of D. immitis clustered with the Wolbachia genomes, providing further 
evidence that they had been acquired by the nucleus through horizontal transfer. 
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Genome-wide survey for ligand gated ion channels in D. immitis 
Having the genome in hands, it was possible to make an inventory of the ligand-
gated ion channels (LGIC). LGIC are divided into different families; one of them, the 
nicotinic acetylcholine receptor (nAChR) family, comprises several targets of 
anthelmintics including the target of the AADs (32). We have identified 24 proteins 
that contain either the ligand-binding or the transmembrane or both of LGIC (Table 
3).  
Table 3. Description of the 24 LGIC receptors of D. immitis, with homology to C. elegans. 
LBD means ligand-binding domains and “memb” is related to the membrane domains of the 
LGIC. E (E (expect)-value): parameter describing the number of hits “expected” to see by 
chance when searching a database with a particular size), Score (number used to assess the 
biological relevance of a finding; it describes the overall quality of an alignment). 
 
Profile Hit E Score Homolog/ 
Best hit in  
(C.elegans) 
Neur_chan_LBD DimmContig1076_DIMM26960 1.5E-33 103.1 lgc-55 
Neur_chan_LBD DimmContig123_DIMM06980 3.6E-50 157.4 lgc-49 
Neur_chan_LBD DimmContig1262_DIMM29165 1.8E-55 174.7 acr-8 
Neur_chan_LBD DimmContig1333_DIMM30000 1.9E-61 194.3 unc-29 
Neur_chan_memb DimmContig14949_DIMM62135 1.2E-19 58.4 unc-49a 
Neur_chan_memb DimmContig160_DIMM08405 3.1E-64 204.4 unc-63 
Neur_chan_LBD DimmContig17_DIMM01370 6.4E-45 140.3 lgc-30 
Neur_chan_LBD DimmContig1990_DIMM36340 2.5E-40 125.2 lgc-26 
Neur_chan_LBD DimmContig206_DIMM09920 9.0E-48 149.6 lgc-46 
Neur_chan_LBD DimmContig226_DIMM10520 4.5E-65 206.1 acr-12 
Neur_chan_LBD DimmContig2623_DIMM41090 8.1E-49 153 lgc-47 
Neur_chan_LBD DimmContig3506_DIMM45965 3.8E-75 239.1 unc-38 
Neur_chan_LBD DimmContig3655_DIMM46615 3.2E-37 115.1 acc-1 
Neur_chan_LBD DimmContig3655_DIMM46620 5.3E-42 130.7 acc-1 
Neur_chan_LBD DimmContig3792_DIMM47160 1.2E-69 221.1 acr-15 
Neur_chan_memb DimmContig3824_DIMM47310 5.5E-35 108.7 lgc-53 
Neur_chan_memb DimmContig3972_DIMM47885 6.3E-23 69.2  
Neur_chan_LBD DimmContig431_DIMM15880 2.9E-50 157.7 lgc-55 
Neur_chan_memb DimmContig464_DIMM16610 2.0E-76 244.3 apr-14 
Neur_chan_memb DimmContig490_DIMM17190 3.3E-13 37.4 lgc-41 
Neur_chan_LBD DimmContig692_DIMM21120 8.6E-46 143.1 glc-2 
Neur_chan_LBD DimmContig747_DIMM22030 9.7E-48 149.5 glc-4 
Neur_chan_LBD DimmContig8745_DIMM57755 2.9E-19 56.4 unc-38 
Neur_chan_LBD DimmContig953_DIMM25280 3.4E-55 173.8 glc-2 
 
Interestingly, amongst those 24 LGIC receptors no members of the DEG-3 such 
family of nAChR is found. This contrasts with B. malayi which possess two DEG-3 
family members.  
The number of LGIC varies among classes and species of organisms. An interesting 
phylogenetic comparison of the number of LGIC was described by Rufener et al.; C. 
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elegans belongs to the clade V in the nematode phylogeny and shows 102 LGIC 
receptors (126). D. immitis is part of the clade III as B. malayi and A. suum. The 
number of LGIC between the filariae, D. immitis and B. malayi, is equivalent to 24 
receptors, while the ascaridae shows 98 LGIC receptors (99). In the recent 
publication of the Ascaris suum draft genome, the authors even claim the presence of 
a homolog to the acr-23 of the free-living nematode. However, the authors failed to 
perform reciprocal blast searches. A simple tblastn search of the claimed homolog 
against C. elegans indicated that the mentioned sequence has a better hit to des-2 of 
C. elegans.  Nevertheless, A. suum genome contains DEG-3 family members; while 
this receptor family is absent in D. immitis. The third publication, “Loss of Deg-3-
subfamily acetylcholine receptors and lack of stereoselective monepantel sensitivity 
in Dirofilaria immitis”, describes in more detail the search for D. immitis LGIC.  
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monepantel sensitivity in Dirofilaria 
immitis 
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In this short communication, I performed in vitro tests with microfilariae of D. immitis, 
coordinated the collection of data, put scientists in relation to continue the tests, draw the 
conclusions and wrote part of the text.  
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The heartworm Dirofilaria immitis is a parasitic nematode of mammals that is transmitted by 
mosquitoes (Culicidae). The definite host is the dog, where adult worms reside in the pulmonary 
arteries and the females shed microfilariae into the bloodstream. Dirofilariasis is a severe disease of 
dogs (Simon et al., 2009). The recommended preventive (Bowman and Atkins, 2009) is 
chemoprophylaxis with macrocyclic lactones (ML; ivermectin, milbemycin oxime, moxidectin, or 
selamectin) which, however, bears the risk of selecting for drug resistant parasites (Bourguinat et al., 
2011). In the absence of a vaccine, new drugs are needed for sustainable control of dirofilariasis. 
Drug development for the heartworm will be of benefit also against the closely related pathogens 
Onchocerca volvulus or Loa loa, the causative agents of neglected human filarial diseases. 
Monepantel (Novartis compound AAD-1566; (Kaminsky et al., 2008)) is a new addition to the 
anthelmintic armory. Monepantel is the first aminoacetonitrile derivative (AAD) to reach the market, 
used under the brand name Zolvix® (Novartis 2010) against gastrointestinal nematodes of sheep such 
as Haemonchus contortus or Trichostrongylus colubriformis. Monepantel is highly effective against 
these parasites (Hosking et al., 2009), including ML-resistant isolates (Baker et al., 2011), and well 
tolerated by the mammalian hosts (Kaminsky et al., 2008). Here we investigate the potential of 
monepantel against dirofilariasis. 
 The efficacy of monepantel was tested against the model filarid Acanthocheilonema viteae in 
gerbils and against D. immitis in dogs. While there was no efficacy in vivo, the EC50 of monepantel 
against D. immitis microfilariae in vitro was 2 μM, even slightly below that of milbemycin oxime 
(Figure 1). Monepantel is thought to act by allosteric hyperactivation of ligand-gated ion channels, 
the known targets comprising ACR-23 in C. elegans, and MPTL-1 and DES-2 in H. contortus. These are 
putative nicotinic acetylcholine receptor (nAChR) subunits of the DEG-3 subfamily, a clade of nAChR 
that only occurs in nematodes. The presence of MPTL-1 or ACR-23 orthologues in helminth genomes 
correlates with monepantel susceptibility (Rufener et al., 2010b), and loss-of-function mutations in 
MPTL-1 and ACR-23 were associated with loss of monepantel sensitivity in H. contortus (Rufener et 
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al., 2009) and C. elegans (Kaminsky et al., 2008), respectively. We have scanned the predicted 
proteome of D. immitis (Godel et al., unpublished/in press) for ligand-gated ion channels with Pfam 
profiles (Punta et al., 2011) specific for the extracellular ligand-binding domain (PF02931) and for the 
membrane ion channel domain (PF02932). Using HMMer (Eddy, 2009) with a conservative cut-off E-
value of <10-10 this yielded 39 hits for the ligand-binding domain, 32 hits for the membrane domain, 
and an intersect of 24 proteins carrying both domains. The same search in C. elegans (Harris et al., 
2011) returned 110 proteins with both domains, which is in agreement with published numbers 
(Jones and Sattelle, 2008). A phylogenetic tree based on the multiple alignment (Thompson et al., 
1994) of the pooled hits obtained from C. elegans and D. immitis revealed that the targets of 
macrocyclic lactones and levamisole are conserved in the heartworm, but those of the 
aminoacetonitrile derivatives are not (Figure 2). In fact, DEG-3 subfamily members seem to be 
completely absent from the D. immitis proteome (Figure 2). This was supported by tblastn searches 
(Altschul et al., 1990) against the D. immitis genomic assembly (Godel et al., unpublished/in press) 
with DEG-3 family sequences, returning but a des-2 pseudogene which carries several in-frame stop 
codons, and which is not transcribed in D. immitis adult worms (data not shown). The presence of 
the des-2 pseudogene in D. immitis, and the presence of both DEG-3 and DES-2 orthologues in Brugia 
malayi (Williamson et al., 2007), suggest that the dirofilarial ancestor had lost the functional DEG-3 
type genes after separation from the line leading to Brugia. Given the absence of DEG-3 subfamily 
nAChR in D. immitis, the activity of monepantel against microfilariae must be directed at another 
target (or targets). 
 Aminoacetonitrile derivatives contain a center of chirality. The active enantiomer 
monepantel is the S-form, the R enantiomer AAD-2224 being 1,000 fold less potent against H. 
contortus or T. colubriformis (Figure 1). The same stereoselectivity is reflected by the action of 
monepantel against ligand-gated ion channels expressed in Xenopus laevis oocytes (Rufener et al., 
2010a). However, the observed in vitro activity of monepantel against D. immitis microfilariae was 
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not stereoselective, the two enantiomers exhibiting the same potency (Figure 1). This result is in 
agreement with the absence of the known, stereoselective monepantel targets in D. immitis (Figure 
2). In summary, we show that monepantel has in vitro activity against D. immitis microfilariae but the 
target, given the absence of DEG-3 genes and the lack of stereoselectivity, is unlikely to be an 
acetylcholine receptor channel. The molecular nature of the monepantel target in the heartworm 
remains to be identified. 
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FIGURE LEGENDS 
 
Figure 1. Structure and in vitro activity of monepantel (AAD-1566) and its mirror image (AAD-2224). 
EC50 values against H. contortus and T. colubriformis were determined with a larval development 
assay (Gill et al., 1995), and against D. immitis with a microfilarial viability assay (Godel et al., 
unpublished). The macrocyclic lactone milbemycin oxime was included as a reference.  
 
 
 
 
 
 
 
 
Figure 2. Phylogenetic tree of the predicted ligand-gated ion channels from C. elegans (grey) and D. 
immitis (red). All proteins were included that tested double positive for the ligand-binding domain 
(PF02931) and the membrane domain (PF02932). The scale bar indicates number of changes per 
residue. The known drug targets of C. elegans are labeled (ML, macrocyclic lactones; AAD, 
aminoacetonitrile derivatives). 
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Deeper investigations through the DEG-3-subfamily 
Additional investigations were performed on this interesting receptor family, DEG-3, 
in D. immitis genome. After blast and reciproqual blast searches, no acr-23, des-2 
and deg-3 homolog were found. Did I miss the receptor(s) to AADs or is/are it/they 
simply absent?  
Another approach was to identify the neighbor genes of acr-23, des-2 and deg-3 in 
C. elegans and B. malayi. A blast search of the neighbor genes in D. immitis genome 
did not help to identify the target receptors of AADs. The neighbor genes are, partly, 
found in D. immitis genome; still no acr-23, des-2 or deg-3. The genes might simply 
not be present. A tblastn search was similarly performed on the adult RNA 
sequences assembly without acr-23, des-2 or deg-3 found, leading to the conclusion 
that none of these receptors are expressed in adults. In the closely related filarial 
nematode Onchocerca volvulus no orthologs to these receptors were so far identified 
(125). 
However, a pseudogene of des-2 has been identified in the genome. To assess the 
presence of the des-2 pseudogene in the genome of D. immitis, a RT-PCR (reverse 
transcriptase) was performed on genomic DNA and complementary DNA with 
primers specific to the des-2 pseudogene (Figure 16). The des-2 pseudogene 
sequence is seen in the genomic DNA and is absent in the complementary DNA; 
concluding that the des-2 pseudogene is not active, not translated into protein.  
 
 
Figure 16. Agarose gel of 1.2% representing the RT-PCR (reverse transcriptase) picture 
performed on the des-2 pseudogene sequence of D. immitis on complementary DNA and 
genomic DNA. Positive controls were performed with beta-tubulin specific to D. immitis. 
Negative controls are without primers or without DNA samples.   
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The aim of the PhD thesis was to characterize the receptor(s) to AADs in the genome 
of D. immitis. However, the absence of the receptor(s) has been proven previously.  
Having the genome assembled, other analyses are possible. In that way, based on 
exclusion criteria a closer study of the genome contigs allowed drawing a picture of 
novel potential drug targets.  
 
In silico novel potential drug targets of D. immitis 
To obtain a table of the novel potential drug targets by in silico filtering methodology, 
filters were applied on the whole proteome of D. immitis using various criteria. A 
similar methodology was applied on the genome of B. malayi by Kumar et al.; 
obtaining 589 potential targets (126). The filters applied were the absence of a blastp 
hit in the predicted proteomes of Homo sapiens and Canis lupus familiaris with an E-
value below 10-5, followed by the presence of an ortholog in C. elegans which has as 
an RNA interference (RNAi) phenotype lethal, L3_arrest, or molt_defective and 
predicted function as an enzyme or receptor based on the annotation of the C. 
elegans ortholog and blastp searches against SwissProt (essential structural proteins 
such as innexin, etc., were excluded) (Table 4). 
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Table 4. Table regrouping the potential drug targets of D. immitis obtained after an exclusion 
criteria study on the whole proteome ((i) presence of an ortholog in C. elegans which has as 
an RNAi phenotype lethal, L3_arrest, or molt_defective; (ii) absence of a blastp hit in the 
predicted proteomes of H. sapiens and C. lupus familiaris with an E-value below 10-5; (iii) 
predicted function as an enzyme or receptor based on the annotation of the C. elegans 
ortholog and blastp searches against SwissProt). 
 
D.immitis protein  Predicted function  Target for  H. sapiens  
log10 (E)  
C. lupus  
log10 (E)  
C. elegans  
RNAi  
Nucleic acid synthesis and repair       
DimmContig1352_DIMM30240 RNA-dependent RNA polymerase Antiviral >1 0.89 lethal 
DimmContig188_DIMM09370 RNA-dependent RNA polymerase  0.28 0.11 lethal 
DimmContig829_DIMM23385 Apurinic/apyrimidinic endonuclease  Anticancer >1 -0.12 lethal 
Glycosylation and sugar metabolism       
DimmContig417_DIMM15590 dTDP-4-dehydrorhamnose3,5-epimerase  0.23 0.04 lethal 
DimmContig51_DIMM03355 Beta-1,4-mannosyltransferase Pesticide 0.95 0.94 lethal 
DimmContig3217_DIMM44525 UDP-galactopyranose mutase Antimycobacterial 0.36 0.08 molt defective 
DimmContig2055_DIMM36945 Chitin synthase Insecticide -3.52 -4.00 lethal 
Lipid metabolism       
DimmContig5517_DIMM52545 Lipase  0.08 -1.60 lethal 
DimmContig338_DIMM13735 Sterol-C24-methyltransferase (Erg11) Antifungal -3.10 -4.00 lethal 
DimmContig1191_DIMM28365 Methyltransferase  -0.03 -0.15 lethal 
Transport       
DimmContig1379_DIMM30520 Aquaporin  -2.05 -0.52 lethal 
Signal transduction       
DimmContig333_DIMM13570 Nuclear hormone receptor  -2.40 -4.52 lethal 
DimmContig245_DIMM11140 G-protein coupled receptor Many indications -1.06 -0.59 lethal 
DimmContig1549_DIMM32395 G-protein coupled receptor Many indications -1.26 -1.57 lethal 
DimmContig2384_DIMM39455 G-protein coupled receptor Many indications -2.70 -1.96 lethal 
DimmContig335_DIMM13610 Groundhog protein Anticancer >1 0.04 lethal 
DimmContig3787_DIMM47150 Warthog  protein Anticancer >1 0.78 lethal 
DimmContig48_DIMM03200 Warthog  protein Anticancer >1 0.32 lethal 
DimmContig253_DIMM11405 Haloacid dehalogenase-like hydrolase  -3.22 -4.00 lethal 
DimmContig326_DIMM13435 Apoptosis regulator ced-9 Anticancer 0.77 -1.02 lethal 
 
The filtering criteria are relevant as a method to discover potential new drug targets. 
However, setting filters can have disadvantages; interesting targets can be missed. 
For example none of the LGIC receptors came out of the research. This is due to 
their relative similarity to the human and dog proteome sequences; knowing that the 
best hits to these proteomes were retrieved. LGIC are nevertheless important 
anthelmintic targets. In mammals, LGIC are present behind the cerebral barrier and 
are not reachable for anthelmintic compounds while nematodes LGIC are well 
exposed to drugs. 
Anyway, about 400 potential drug targets came out from this filtering research. Over 
this large number of targets 298 are functionally unknown proteins. These putative 
proteins are currently unhelpful to discover new anthelmintics.  
C h a p t e r  4   P a g e  | 120 
 
 
Focusing on the potential novel drug targets with known properties interesting 
conclusions might point out.  
Over the 20 novel potential drug targets described (table 4), five main groups 
emerged; nucleic acid synthesis and repair, glycosylation and sugar metabolism, lipid 
metabolism, transport, and signal transduction. 
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Chapter 5. Drug sensitivity tests 
(unpublished) 
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While there was no candidate target of monepantel in the predicted proteome of D. 
immitis, we identified by comparative genomics to C. elegans and the dog, several 
other candidate drug targets (see Table 4, page 118). Of these, RNA-dependant 
RNA polymerase and chitin synthase were studied in more detail.  
 
RNA-dependant RNA polymerase  
An RNA-dependant RNA polymerase is encoded in the genome of the heartworm, so 
there might be activity against D. immitis of guanosine analogs, known inhibitors of 
the viral RNA-dependant RNA polymerase. To test this hypothesis, in vitro tests were 
performed with different guanosine analogs. 21 compounds, diluted in dimethyl 
sulfoxide (DMSO), were tested against microfilariae of D. immitis in vitro and the 
efficacy was evaluated after 48 hours of incubation. The maximum concentration 
value tested was 32 ppm. Positive and negative controls were included in the study. 
None of the compound showed activity against the parasite tested (Figure 17). 
Compound 9 was the most active of the guanosine analogs and had an efficacy 
value of 16%. 
 
Figure 17. Percentage of efficacy (absence of motility), in logarithm, of 21 guanosine 
analogs against D. immitis microfilariae at 32 ppm after 48 hours of incubation. Test 
performed in triplicates.  
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Chitin synthase 
Derivatives of lufenuron are commercially available and they are mainly used as 
insecticides. Seven putative chitin synthase inhibitors were tested in vitro against D. 
immitis microfilariae. Figure 18 illustrates the percentage of efficacy of lufenuron and 
6 derivatives against D. immitis microfilariae after 48 hours of in vitro incubation. 
Ivermectin and milbemycin oxime were included as controls. A good efficacy is 
considered to be between 80 and 100%.  
 
Figure 18. Percentage of efficacy at 32 ppm (particle per million) of in vitro tests with 
Lufenuron and six derivatives against D. immitis microfilariae after 48 hours incubation. Test 
performed in triplicates. 
 
No significant efficacy was seen in this in vitro test. The control, milbemycin oxime, is 
good; efficacy reaching 91% after 48 hours at 32 ppm. Ivermectin showed 30.6% of 
efficacy; however this is a known phenomenon in microfilarial in vitro screening due 
to a paralysis of the larvae. The lufenuron analogs have a lower percentage of 
efficacy than lufenuron; except triflumuron which had an efficacy of 46.6% at 32 ppm 
after 48 hours incubation. The microfilarial in vitro test may not be suitable for efficacy 
testing of chitin synthase inhibitors. These could be assumed to exhibit maximal 
activity during molting of the subsequent larval stages and development of eggs in 
adult females.  
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Potential novel receptors of Wolbachia, endosymbiont of D. immitis 
An in silico study was performed on the Wolbachia genome of D. immitis to identify 
potential novel drug targets. Table 5 summarizes candidate targets with annotation in 
Escherichia coli and corresponding sequences of Wolbachia.  
Table 5. Potential drug targets of the heartworm endosymbiont, Wolbachia pipientis. As 
identified by the following exclusion criteria: (i) presence of orthologs in E. coli which are 
essential; (ii) absence of a blastp hit in the predicted proteomes of H. sapiens and C. lupus 
familiaris with an E-value below 10-5; (iii) predicted function as an enzyme or receptor based 
on the annotation of the E. coli ortholog and blastp searches against SwissProt. 
 
wDi protein logE (dog) logE (human) Ecoli ortholog Ecoli annotation
fig|82301.4.peg.250 -0.39 -0.46 FTSA Essential cell division protein FtsA
fig|82301.4.peg.329 -0.74 -1.68 FTSZ Essential cell division protein FtsZ
fig|82301.4.peg.797 -2.40 -2.22 ACPS Holo-[acyl-carrier-protein] synthase
fig|82301.4.peg.229 -3.70 -5.05 BIRA Bifunctional biotin-[acetyl-CoA-carboxylase] ligase and transcriptional repressor
fig|82301.4.peg.765 0.00 0.34 FABZ 3-hydroxy-acyl-[acyl-carrier-protein] dehydratase
fig|82301.4.peg.97 -0.62 0.28 DNAA Chromosomal replication initiator protein
fig|82301.4.peg.645 -2.05 -1.96 DNAB Replicative DNA helicase
fig|82301.4.peg.298 -0.46 0.74 RPOA RpoA is the α subunit of the RNA polymerase core enzyme
fig|82301.4.peg.817 -1.46 >1 TRMD tRNA (m
1
G37)methyltransferase catalyzes the addition of a methyl group to
G37 of certain tRNAs
fig|82301.4.peg.753 -5.22 -5.15 MRAY Phospho-N-acetylmuramoyl-pentapeptide transferase catalyzes the first step of
the lipid cycle reactions in the biosynthetic pathway of cell wall peptidoglycans
fig|82301.4.peg.796 -0.27 0.92 MURA UDP-N -acetylglucosamine enolpyruvoyl transferase (MurA) catalyzes the first
committed step in the assembly of peptidoglycan
fig|82301.4.peg.490 -0.46 0.23 MURB murB encodes the UDP-N -acetylenolpyruvoylglucosamine reductase which
catalyzes the second committed step in the biosynthesis of peptidoglycan
fig|82301.4.peg.810 0.20 0.64 MURC UDP-N-acetylmuramate-alanine ligase is responsible for the addition of the first
amino acid of the peptide moiety in the assembly of the monomer unit of
peptidoglycan
fig|82301.4.peg.34 -0.89 -0.60 MURD Biosynthesis of peptidoglycan
fig|82301.4.peg.12 -0.12 0.86 MURE Biosynthesis of peptidoglycan
fig|82301.4.peg.706 -0.06 0.66 MURG murG gene codes for the N-acetylglucosaminyl transferase responsible for the
final intracellular step of peptidoglycan subunit assembly
fig|82301.4.peg.79 -0.80 -0.42 MVIN MurJ is an essential gene involved in murein synthesis as the flippase
responsible for transport of lipid II from the inner face of the inner membrane to
the outer face for polymerization
fig|82301.4.peg.556 0.23 0.36 SECA Inner membrane component of the Sec Protein secretion system
fig|82301.4.peg.488 0.20 0.48 SECD Component of the Sec Protein secretion system
fig|82301.4.peg.154 -0.23 -0.96 SECF Component of the Sec Protein secretion system
fig|82301.4.peg.294 -0.19 0.18 SECY Component of the Sec Protein secretion system
fig|82301.4.peg.499 -0.06 0.46 YFIO BamD as forming a large protein complex with BamB involved in outer
membrane protein (OMP) biogenesis
fig|82301.4.peg.621 0.68 >1 LOLE Membrane component of the LolCDE lipoprotein transporter, ABC transporter
fig|82301.4.peg.512 0.85 >1 RIBB RibB catalyzes the synthesis of the 4-carbon compound 3,4-dihydroxy-2-
butanone-4-phosphate, a precursor of the terminal intermediate, 6,7-dimethyl-8-
ribityllumazine, in the biosynthesis of riboflavin
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A selection of antibiotics was tested in the same microfilarial in vitro assay (Figure 
19). 
 
Figure 19. Percentage of efficacy,  logarythm scale, of nine antibiotics potentially targeting 
Wolbachia of D. immitis. Test performed against D. immitis microfilariae at 32 ppm after 48 
hours of incubation and in triplicates. 
 
Only tetracyclin exhibited 100% efficacy. Four other compounds (oxacilin sodium salt, 
penicillin G potassium salt, tiamulin fumarate and tiamulin hydrogen fumarate) were 
slightly active with, respectively, 3.7, 1.3, 3.7 and 10.3% efficacy.  
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Discussion 
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The initial hypothesis of the PhD thesis was that D. immitis possesses an MPTL-1 
ortholog because it shows susceptibility to AADs in vitro. The aim had been to 
discover that ortholog, and to identify LGIC in general. For this purpose, we 
sequenced the D. immitis genome. Having the full genome sequence in hands, 
deeper investigations were performed to identify and characterize LGIC in silico 
based on phylogenetic comparisons. Based on the obtained results, potential drug 
targets of D. immitis were identified. However, not a single member of the DEG-3 
subfamily of acetylcholine receptors, which contains the target of monepantel, was 
found; except for a pseudogene, corroborating the hypothesis that these receptors 
were lost during the evolution of D. immitis. The most interesting targets were 
compiled in Table 4 (page 119) and further investigations were performed to correlate 
drug susceptibility with the presence or absence of target(s). The focus was put on 
enzymes involved in (1) the nucleic acid synthesis and repair, and (2) sugar 
metabolism and glycosylation.  
 
1. Nucleic acid synthesis and repair receptors 
RNA-dependant RNA polymerase 
An RNA-dependant RNA polymerase is an enzyme that catalyses the synthesis of an 
RNA complementary strand from an RNA template (127). The protein is essential in 
RNA viruses, and all known RNA viruses encode RNA-dependent RNA polymerase. 
RNA viruses are divided into three major classes; SSRNA positive strand, SSRNA 
negative strand, and dsRNA genome (128). RNA-dependent RNA polymerases are 
crucial for the replication of all 3 classes RNA viruses. The C. elegans enzyme has a 
lethal RNAi phenotype (166). 
The RNA-dependent RNA polymerase of D. immitis may be a novel potential 
anthelmintic target, since there is no mammalian ortholog.  
 
Unfortunately, however, there are no known inhibitors of metazoan RNA-dependant 
RNA polymerase. Thus we tested inhibitors of the viral enzymes, guanosine analogs 
in particular. Acyclovir is an important antiviral low cytotoxicity and a good specificity 
against herpes zoster (shingles), genital and labial herpes, and chickenpox. Acyclovir 
molecule after absorption by the host cell is converted to the monophosphate by viral 
thymidin kinase; followed by conversion to the triphosphate form, acido-GTP, which 
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is a powerful inhibitor of the viral RNA-dependent RNA polymerase (128). Aciclovir 
and all other antivirals tested were inactive against D. immitis microfilariae (Figure 17 
page 122, Chapter 5).  
 
This could be explained by different reasons. RNA-dependent RNA polymerase 
might not be essential, at least not at this life stage or it might be insensitive to 
guanosine analogs. In summary, eukaryotic RNA-dependant RNA polymerases might 
be attractive new antiparasitic drug targets, but proof of principle is lacking as there 
are no validated inhibitors.  
 
2. Glycosylation and sugar metabolism 
Glycosylation and sugar metabolic enzymes represent another encouraging group of 
potential novel drug targets. Among this category, three predicted enzymerase of 
particular interest: beta-1,4-mannosyltransferase, UDP-galactopyranose mutase and 
chitin synthase. The C.elegans RNAi phenotype is lethal for two of them while for the 
UDP-galactopyranose mutase the RNAi phenotype is molt defective (which would 
suffice for a heartworm preventive).  
 
Beta-1,4-mannosyltransferase 
In C. elegans, beta-1,4-mannosyltransferase is alternatively named Bacillus 
thuringiensis toxin-resistant, BRE-3. Cry5B toxin is produced by B. thuringiensis, 
NP499087.2 (130). 
BRE-3 belongs to the glycosyltransferase-2 family (E.C. 2.4.1 group of 
hexosyltransferase) (131). Its proposed role is in glycosphingolipid biosynthesis and it 
is involved in susceptibility to pore-forming toxins in conjunction with BRE-1, BRE-2, 
BRE-4 and BRE-5 (132).  
The Gram-positive B. thuringiensis is a soil-dwelling bacterium that was discovered 
by the Japanese biologist S. Ishiwatari in 1901. In 1911 E. Berliner, a German 
biologist, rediscovered the bacteria searching for a cause of a disease in caterpillar 
(132-133). These aerobic bacteria are able of producing endospores. The production 
of crystal proteins, δ-endotoxins with insecticidal activity, occurs during sporulation. 
However, many crystal-producing B. thuringiensis strains do not have insecticidal 
properties (134). 
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Beta-1,4-mannosyltransferase builds the target of the Bt toxins (B. thuringiensis) and 
an ortholog of bre-3, is encoded in the genome of D. immitis, meaning that the target 
is likely present. 
Extracted from bacteria, these Bt toxins are mainly used in agriculture as natural 
insecticides. When the insects ingest the Cry proteins, they insert into the membrane 
and form a pore in the intestine wall of the insect gut. The pore results in cells lysis 
and potential death of the insect within 2 to 5 days (135). Bre-3 encodes a protein 
similar to beta-glycosyltransferases from bacteria that is required for the toxicity of B. 
thiuringiensis Cry5B. B. thuringiensis products have a narrow spectrum of activity and 
are considered non-toxic to humans, other mammals and plants and of less damage 
than other insecticides (136).  
B. thuringiensis expresses crystal protein toxins of various types. The number of 
known crystal proteins, Cry and Cyt proteins has drastically increased in the last 
decades to over 600 different δ-endotoxins (137-139). Amongst these, a few seems 
to have nematicidal properties.  
Already in 1987, Bottjer and Bone described morphological changes of eggs and 
juveniles, and death in the gastro-intestinal nematode T. colubriformis after 
immersion in a crystal-enriched preparation of B. thuringiensis israelensis (133). 
Later on, Edwards et al. from Mycogen, patented novel isolates of B. thuringiensis 
containing toxin active against adult nematodes and larvae (139). Between 1996 and 
2010, various authors described the B. thuringiensis δ-endotoxins having nematicidal 
effects on C. elegans (140-143), Ancylostoma ceylanicum (135) and 
Heligmosomoides bakeri (144). Two other publications (145-146) reported the activity 
of the Bt toxins against diverse nematodes.  
Cry proteins must be ingested to intoxicate. In the case of A. ceylanicum, it is not 
surprising that none-feeding stages are not susceptible to Cry5B toxicity; the other 
stages being susceptible (135). Diverse crystal proteins show nematicidal activity, 
Cry5, Cry6, Cry12, Cry13, Cry14 and Cry21. The Cry5B crystal protein has been 
shown to be therapeutic in vivo against the intestinal hookworm, A. ceylanicum, in 
hamsters when delivered daily per os over the course of 3 days (135). Aroian R. et al. 
(147) showed that Cry5B had significant anthelmintic activity in rodent models 
against two parasitic nematodes, H. bakeri and Trichuris muris. The Cry5B is a huge 
protein with 150kDa and it appears to be rapidly degraded in the stomach with less 
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than 1% reaching the parasite. There is a quick release of the product in the 
mammalian body and within two hours the protein is dispersed (147).  
In the case of D. immitis, very little information is known about the feeding processes. 
D. immitis feed primarily on blood or plasma in and around the heart and lungs. 
Would the heartworm ingest δ-endotoxins and could they be used as anthelmintics? 
Currently, we do not know anything on the efficacy of B. thuringiensis toxins against 
D. immitis. The best way would be to test Cry5B in vitro against microfilariae and L3 of 
D. immitis. As a positive control, Cry5B should be tested in the LDA against 
Haemonchus contortus, a blood feeding gastro-intestinal nematode. Before testing 
the protein, the nematicidal spore-crystal mixture of B. thuringiensis needs to be 
obtained. The preparation of the crystal protein was described in Borgonie et al. and 
might be feasible (140). 
 
UDP-galactopyranose mutase 
The second enzyme of interest in the glycolysation and sugar metabolism group is 
UDP-galactopyranose mutase (E.C. 5.4.99.9), a known antimycobacterial target.  
UDP-galactopyranose mutase is a flavoenzyme involved into bacterial cell wall 
biosynthesis by catalyzing the conversion of UDP-D-galactopyranose to UDP-D-
galacto-1,4-furanose (148). This product is found in bacterial cell walls, including 
those of many pathogens (149). UDP-D-galacto-1,4-furanose is an essential sugar 
for the growth of pathogenic bacteria and survival in the host. Importantly, the 
enzyme has not been found in mammals. The D-galactofuranose is also a 
component of the cell envelope of eukaryotic parasites, as Leishmania spp, 
Trypanosoma cruzi, and of a number of different fungal species including Penicillium 
spp and Aspergillus spp (150). 
UDP-galactopyranose mutase homologs are found in most of the nematode clades, 
suggesting an ancient and conserved feature of the phylum. Novelli et al. (151) 
described a detailed genetic and molecular analysis of the C.  elegans homolog, glf-
1. They demonstrated galactofuranose synthesis in the free-living nematode and its 
importance in the maintenance of the integrity of the coat surface. Additionally, 
genome-wide RNAi screens showed the roles of the synthesis in nematode survival, 
in late larval development, and in the completion of embryogenesis (151). UDP-
galactopyranose mutase was also proposed as a target against B. malayi (126). An 
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Australian patent describes an UDP-galactopyranose mutase derived from parasitic 
nematodes and specifically the gastro-intestinal nematode H. contortus as potential 
drug target (152).  
A first step forward validation of UDP-galactopyranose mutase as a drug target of D. 
immitis would be in vitro tests with proven UDP-galactopyranose inhibitors. Diverse 
studies have been performed to identify inhibitors of UDP-galactopyranose mutase. 
Partha et al. identified three best groups of inhibitors, the substituted thiazolidinones, 
the aminothiazoles and the pyrazoles (153).  
Thiazolidinones are derivatives of thiazolidine. They belong to an important group of 
heterocyclic compounds with sulfur and nitrogen in a five-membered ring. The 
different derivatives have various biological activities (154-155), including 
antibacterial, antitumor, antihistaminic, anti-inflammatory, and anticonvulsant (156). 
One of the best studied groups is the 4-thiazolidinones; derivatives of thiazolidine 
with a carboxyl group at the 4 position (155).  
2-aminothiazoles are small molecules of heterocyclic amine with antiprion activity.  
Dykhuizen et al. show that 2-aminothiazoles target the UDP-sugar binding site of 
UDP-galactopyranose mutase and validate UDP-galactopyranose mutase as an 
antimycobacterial target (157). 2-aminothiazoles are not yet commercially available.  
Last group of potential inhibitors of UDP-galactopyranose mutase are the pyrazoles 
also known as 1,2-diazoles. The basic structure is represented by simple aromatic, 5-
membered ring composed of three carbon and two nitrogen atoms in adjacent 
positions. Biological properties of pyrazoles are wide; playing a role in inflammation, 
diabetes, as antibacterials, analgesics, for anti-arrhythmia, as tranquilizers, for 
muscular soothing and so on (158). Again pyrazoles are not easily commercially 
available.   
In conclusion, UDP-galactopyranose mutase could be an attractive antifilarial target 
that could be validated by thiazolidinones, 2-aminothiazoles or pyrazoles. However, 
these would be needed to be synthesized. 
Chitin synthase 
Chitin synthase (E.C. 2.4.1.16) catalyzes the polymerization of UDP-N-acetyl-β-D-
glucosamine to give the insoluble biopolymer chitin, poly-β(1,4)-GlucNAc. This 
natural amino-polysaccharide is synthesized by certain invertebrates such as fungi, 
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parasitic nematodes, insects and protozoa. The interest of the chitin synthesis is the 
fundamentality of the process in many of these organisms while it is totally absent in 
mammals. Consequently, chitin synthase is an attractive target for drug discovery 
(159). Currently, chitin synthase is mainly used as insecticide target. Chitin is an 
important component of the insect exoskeleton and nematode egg shell (160). In the 
viviparous D. immitis, the embryo hatches from the eggshell into the maternal uterus. 
Microfilariae are shed from the female without extracuticular structures (161). Even 
with this pattern of embryogenesis the chs-1, chitin synthase, gene is present in the 
genome. One proposed inhibitor of chitin synthase is lufenuron. Lufenuron is the 
active ingredient of the flea control medication Program®. This compound breaks the 
flea life cycle by inhibiting the development of the egg, interfering with chitin synthesis 
and deposition. At therapeutical doses, lufenuron has no effects against adult fleas. 
Lufenuron is stored in the body fat of the animal and transferred to the adult flea 
through their bite. The product reaches the eggs through the blood circulation or by 
the larva feeding on pre-digested blood. Lufenuron is also efficacious in crop 
protection against lepidoptera, mites and thrips; additionally it is effective as an anti-
fungal in plants. It is non toxic to mammals (162). In the medication Program plus®, 
Lufenuron is combined with milbemycin oxime, a ML, against larval stages of D. 
immitis infections as well as fleas. Program plus® is given in dogs against ecto- and 
endo-parasites (163).  
 
3. Parallel study performed on Wolbachia of D. immitis 
Potential target were also predicted from the proteome of D. immitis endosymbiont 
Wolbachia. Table 5 (page 124, Chapter 5) summarizes the potential drug targets of 
Wolbachia that are essential for Escherichia coli.  
Wolbachia are alphaproteobacteria showing a mutualistic relationship with filarial 
nematodes. Related to Rickettsia and Ehrlichia, the obligate endosymbiont is located 
in most tissues of the nematodes and mainly in hypodermal cords. The 
endosymbionts’ transmission occurs between the filarial adult female and its offspring 
through oocytes. Tetracycline is effective against O. volvulus and raised hopes for 
further antibiotics active against filariae (164). Without their endosymbiont, filariae 
show a loss of fertility and viability (165). However, the endosymbiont might be 
difficult to reach as further membranes would need to be crossed. More importantly, 
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the prophylactic use of antibiotics in dogs should be discouraged because of the 
inevitable risk of selecting for drug-resistant bacteria.  
No further studies were performed based on the data shown in the Table 5 (page 
124, Chapter 5).  
C o n c l u s i o n s   P a g e  | 134 
 
 
 
 
 
 
 
 
Conclusions  
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Being aware of the presence or absence of the receptors in the target parasite can 
be very helpful to select novel drugs. For once the mode of action will be known 
before the effect of the drug.  
The genome also brought answers concerning the effect of known anthelmintics as 
macrocylic lactones, benzimidazoles, imidazothiazoles, cyclodepsipeptides, and 
amino acetonitriles derivatives by revealing the presence or absence of specific 
receptors to these anthelmintics.  
 
The unknown target list has a greater number of candidates with unknown functions. 
Further researches are expected to decrease the number of unknown targets. Simple 
modifications can be mentioned as changing the filters or add some more, to reduce 
the number of potential targets in the unknown list; fit new filters as molecular weight 
>100kDa, transmembrane domains, specific domains, paralogs, mutation-non 
mutation, and check for known domains in the sequences using interesting 
databases as target DB and chEMBL,... Eventually, we will end with a reduce list of 
unknown potential drug targets. Later, a colorimetry assay with C. elegans can be set 
to localize the function of the unknown target. Otherwise, functional screening assays 
can be performed as cellular assays. 
 
The use of molecular approaches in the race against parasites and anthelmintic 
resistance might be a great advantage.  
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List of abbreviations 
Abbreviation Translation 
3’-OH Link at 3’ end with oxygen-hydrogen 
5-HT Serotonin 
18S ribosomal RNA S : Svedberg units 
A Adenine 
AAD / AADs Amino Acetonitrile Derivatives 
ABC-transporters ATP-binding cassettes transporters 
ABySS Assembly by short sequences 
ACh Acetylcholine 
A. ceylanicum Ancylostoma ceylanicum 
AcpS Acyl carrier protein synthase 
acr-23 / ACR-23 Acetylcholin receptors 
AH Animal Health 
A. suum Ascaris suum 
ATG Signals start of translation 
ATP Adenosine triphosphate 
A. viteae Acanthocheilonema viteae 
blastp Basic local alignment search tool protein-protein 
blastn Basic local alignment search tool nucleotide-
nucleotide 
blastx Basic lical alignment search tool using a 
translated nucleotide query 
B. malayi Brugia malayi 
bp base pair 
bre-3 (-1, -2, -4, -5) Bt toxins resistant 
Bt Bacillus thuringiensis 
B. thuringiensis Bacillus thuringiensis 
BZT Benzimithiazoles 
C Cytosine 
Ca2+ Calcium 
CAP Companion Animal Parasiticides 
ccmB Heme exporter protein B 
CD4 Cluster of differentiation 4, glycoprotein 
CD-Hit Cluster database at high identity with tolerance 
CEGMA Core eukaryotic gene mapping approach 
C. elegans Caenorhabditis elegans 
chs-1 Chitin synthase gene 1 
Cl- Chloride 
C. lupus familiaris Canis lupus familiaris 
CoA Coenzyme A 
Cry proteins (Cry-5 (-6, -12, -
13, -14, -21) 
Crystal proteins 
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Cry5B Crystal proteins 5B 
Ctrl+ / Ctrl- Control + / Control - 
Cyto Cytosolic 
Cyt proteins Cytolitic proteins 
DB Database 
dbEST EST database 
ddATP, ddCTP, ddGTP, 
ddTTP 
Dideoxyribonucleotide (A, C, G, T) 
deg-3 / DEG-3 Degeneration of certain neurons 
des-2 / DES-2 Degeneration suppressors 
DHFR Dihydrofolate reductase 
D. immitis Dirofilaria immitis 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic acid 
DnaB Mobile replication promoter signal for primase 
dNTP Mix of the four dideoxyribonucleosides 
DOXP 1-dioxy-D-xylulose 5-phosphate 
dsRNA Double stranded RNA 
dTDP Thymidine diphosphate 
EC 90 Efficacy concentration at 90% 
EC 50 Efficacy concentration at 50% 
E.C. Enzyme commission 
E. coli Escherichia coli 
ED 50 Effective dose that cures 50% 
EMBL-EBI European Molecular Biology Laboratory – 
European Bioinformatics Institute 
EMBOSS European Molecular Biology Open Software 
Suite 
ENT-1 Equilibrated nucleoside transporter 
ePCR Emulsion PCR 
erg-11 Ergosterol biosynthesis  
ESTs Expressed sequence tags 
E-value Expected value 
FabZ Encodes for beta-hydroxyacyl-acyl carrier 
protein dehydratases in E. coli 
FAD Flacin adenine dinucleotide 
FDA US Food and Drug Administration 
FtsZ Filamenting temperature-sensitive mutant Z 
G Guanine 
g Gram 
GA Genome analyzer 
GA, Athens Georgia 
GABAA / GABAB Gamma aminobutyric acid A or B 
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Gb Giga base 
G. duodenalis Giardia duodenalis 
GI Gastro-intestinal 
glf-1 Galactofuranose synthesis (UDp-galactopyranose 
mutase) 
GluR Glutamate receptors 
GMP Guanosine monophosphate 
GPCR G protein-coupled receptors 
GPI Gylcophosphatidylinositol 
GTP Guanosine triphosphate 
GTR+ Generalised time-reversible 
HARD Heartworm associated respiratory disease 
H. bakeri Heligmosomoides bakeri 
HBSS Hank’s Balanced Salt Solution 
H. contortus Haemonchus contortus 
hemG Hemin 
hemJ Transformation in heme synthesis 
hemY Protoheme IX synthesis protein 
HMM Hidden markov model (statistic) 
HMMer Sequence analyzer 
H. sapiens Homo sapiens 
IC 50 Inhibitory concentration of 50% 
IL-4, -16 Interleukine 4, -16 
IM Immune modulator 
K+ Potassium 
K / k-mers Quantity or number of amino acid sequences 
Kb Kilo base 
kDa Kilo Dalton 
L3 Third stage larvae 
L3_arrest L3 developmental stage arrest 
LAP Liver-enriched transcriptional activator protein 
LBD Ligand binding domain 
Ld Ladder 
LD 50 Lethal dose that kills 50% 
LDA Larval development assay 
LGIC Ligand-gated ion channels 
L. Loa Loa loa 
Log Logarithm 
L. sigmodontis Litomosoides sigmodontis 
LTR Long terminal repeat 
MAKER Genome annotation pipeline 
Mb Mega base 
mBm Mitochondria B. malayi 
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mDi Mitochondria D.immitis 
mdr-1 Multi drug resistant gene 1 
Memb Membrane domain 
mf Microfilariae 
MIT Massachusetts Institute Technology 
ml Millilitres 
ML / MLs Macrocyclic lactones 
Molt_defective Defective molting stage 
mptl-1 / MPTL-1 Monepantel 
mg/kg Miligrams per kilograms 
MIF Macrophage migration inhibiton factor 
mRNA Mitochondrial RNA 
MUMMER Program to align genome 
µg Micrograms 
Ns Number of N in contigs (gaps) 
N50 Statistical measure of average length of a set of 
sequences 
Na+ Sodium 
NADH Nicotinamide adenine dinucleotide 
nAChR Nicotinic acetylcholine receptors 
NHGRI National Human Genome Research Institute 
nm Nanometers 
NUCMER Nucleotide Mumer 
NTR gene Nitrogenase and nitrate reductase gene 
O. ochengi Onchocerca ochengi 
O. volvulus Onchocerca volvulus 
P2 Aminopurine permease 
P2X ATP-gated purine receptors 
PAO /BEL Subclass of LTR retrotransposon 
PCR Polymerase chain reaction  
PDZ-domain Acronym combining the first letters of three 
proteins — post synaptic density protein 
(PSD95), Drosophila disc large tumor 
suppressor (Dlg1), and zonula occludens-1 
protein (zo-1) 
Per os Oral administration 
PFAM Large collection of protein families, represented 
by multiple sequence alignments and hidden 
Markov models (HMMs) 
P-glycoproteins Permeability glycoproteins 
PhD Doctor of Phylosophy 
PHRAP DNA sequence assembler 
P. falciparum Plasmodium falciparum 
ppm Particles per millions 
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PRPP 5-phosphoribosyl pyrophosphate 
RAxML Randomized Axelerated Maximum Likelihood 
RNA Ribonucleic acid 
RNAi RNA interference 
RNA-Seq Whole transcriptome shotgun sequencing 
R. norvegicus Rattus norvegicus 
RT-PCR Reverse-transcriptase PCR 
Sec Secretory pathway 
Sec Secreted 
SEM Scanning electron microscopy 
seq Sequencing 
SH2 domain Src Homology 2 
SLO-1 Encodes a voltage and calcium activated 
potassium channel 
SMRT Single molecule real time 
SNAP Gene finder based on HMM 
SNPs Single nucleotide polymorphism 
SOAP de novo Short oligonucleotide analysis package 
SOCS Suppressors of cytokine signalling 
SOLID Sequencing by oligo ligation / detection 
Spp. Species 
SSRNA Simple strand RNA chain (virus) 
Src Family of proto-oncogenic tyrosine kinases 
T Thymine 
TbAT1 Gene encoding the aminopurine permease 
tblastn Basic local alignment search tool protein-
nucleotide translation 
T. b. rhodensiense Trypanosoma brucei rhodensiense 
T. colubriformis Trichostrongylus colubriformis 
T. cruzi Trypanosoma cruzi 
TH1 T helper cell 1 
TMI-TMIV / M1-M4 Transmembrane domains 1-4 
tRNA Transfer RNA 
T. vaginalis Trichomonas vaginalis 
UDP Uridine diphosphate 
US United States 
VC  Vaccine candidates 
wBi Wolbachia of B. malayi 
wDi  Wolbachia of D. immitis 
wMel Wolbachia of Drosophila melanogaster  
W. bancrofti Wuchereria bancrofti Wolbachia of Drosophila 
melanogaster 
WO bacteriophage Mobile element in the genome of Wolbachia 
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List of figures 
Figure 1. Third stage larvae of D. immitis. SEM picture showing the worm cuticle details. 
Figure 2. Phylogeny of nematodes based on 18S ribosomal RNA (1). 
Figure 3. US prevalence of antigen positive tests to D. immitis in dogs per county. Counties 
in grey did not reported results. In white, no dog reported as positive (0%). Remaining 
counties were coded as follows: 0.1–2.0% (taupe), 2.1–4.0% (salmon), 4.1–6.0% (red), 6.1–
20.0% (brick red 
Figure 4. Repartition of D. immitis in Europe. 
Figure 5. D. immitis life cycle. 
Figure 6. Susceptible and non-suscepticle ages of heartworm to Macrocyclic lactones and 
melarsomine based upon the age of the worm in days. 
Figure 7. Illustration of the Sanger dideoxy method for DNA sequencing. Addition of 
primers, DNA polymerase and labeled dideoxyribonucleotides, lacking the 3’ hydroxyl group, 
to a mix of DNA simple strand. Without the 3’ hydroxyl group, reactions are stopped 
producing a group of DNA strands of various sizes. These products are separated by size on 
electrophoresis gels. The labeled nucleotides allow the reading of the sequences over the 
four columns of the gel. See text for explanation. 
Figure 8. Decreasing costs to sequence a human genome over 10 years. 
Figure 9.  Illumina Hiseq. Sequencing workflow of the Genome Analyzer. A. Generation of 
sequencing libraries by random fragmentation of DNA strand and ligation of adapters at both 
ends of the fragment. B. Addition of fragment to the flow cell coated with complementary 
oligonucleotides. It is followed by the formation of bridges by hybridization and the 
amplification of the 3’ to 5’ in order to form clusters. C. A denaturation step occurs followed 
by the addition of primers, polymerase and labeled nucleotides. The surface is imaged and 
the process can be repeated. 
Figure 10. Illustration representing the mode of action and localization of numerous different 
anthelmintics at the neuromuscular junction. The different class of drug represented have 
specific mode of action, targeting for example tubulins for the benzimidazoles, calcium 
channels for the cyclodepsipeptides and potassium-natrium channels for avermectins. 
Related to each class, some drug names are given as example. 
Figure 11. Schematic representation of nicotinic acetylcholine receptors protein with the 
four transmembrane domains (M1-M4), the extracellular chain with the N-terminal and 
glycolysation sites and the intracellular domain with the cys-loop. 
Figure 12. Pentameric nicotinic acetylcholine receptor. The neurotransmitter binds to the 
receptor and allows the cation flow through the channel causing muscular contractions 
Figure 13. Monepantel (AAD 2225) activity in four in vitro tests and one in vivo test. 
Concerning the in vitro tests, the efficacy against microfilariae or L3 is evaluated after 48 
hours of incubation with the compounds. In the LDA, egg to L3, the incubation time is longer 
with duration of seven days. The results are represented in ppm (particle per million). In vivo, 
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compounds are applied per os at 40 mg/kg. The efficacy is evaluated at necropsy, by count 
of the adult parasites. Efficacy is defined by comparison to positive control, milbemycin 
oxime, and a low concentration in ppm. 
Figure 14. In vitro efficacies of AADs against D. immitis and A.viteae microfilariae; the tests 
were performed in triplicates. Results are represented in ppm (particle per million). Efficacy is 
defined by comparison to positive control, milbemycin oxime, and a low concentration in 
ppm. 
Figure 15. In vitro efficacies of AADs against gastro-intestinal nematodes in the LDA, from 
egg to L3 were evaluated after seven days of incubation. In vitro efficacies of AADs were 
evaluated against D. immitis and A.viteae microfilariae after 72 hours of incubation all tests 
were performed in triplicates. Results are represented in ppm (particle per million).  
Figure 16. Agarose gel of 1.2% representing the RT-PCR (reverse transcriptase) picture 
performed on the des-2 pseudogene sequence of D. immitis on complementary DNA and 
genomic DNA. Positive controls were performed with beta-tubulin specific to D. immitis. 
Negative controls are without primers or without DNA samples.  
Figure 17. Percentage of efficacy, in logarithm, of 21 guanosine analogs against D. immitis 
microfilariae at 32 ppm after 48 hours of incubation. Test performed in triplicates. 
Figure 18. Percentage of efficacy at 32 ppm (particle per million) of in vitro tests with 
Lufenuron and six derivatives against D. immitis microfilariae after 48 hours incubation. Test 
performed in triplicates. 
Figure 19. Percentage of efficacy, logarythm  scale, of nine antibiotics potentially targeting 
Wolbachia of D. immitis. Test performed against D. immitis microfilariae at 32 ppm after 48 
hours of incubation and in triplicates. 
List of Tables 
Table 1. Summary of different methods of high-throughput sequencing and their specific 
characteristics.  
Table 2. Comparison between various animal species of the genome size, number of 
ligand-gated ion channels and the sequencing method for the genome studies.  
Table 3. Description of the 24 LGIC receptors of D. immitis, with homology to C. elegans. 
LBD means ligand-binding domains and “memb” is related to the membrane domains of the 
LGIC. E (E (expect)-value): parameter describing the number of hits “expected” to see by 
chance when searching a database with a particular size), Score (number used to assess the 
biological relevance of a finding; it describes the overall quality of an alignment). 
Table 4. Table regrouping the potential drug targets of D. immitis obtained after an 
exclusion criteria study on the whole proteome ((i) presence of an ortholog in C. elegans 
which has as an RNAi phenotype lethal, L3_arrest, or molt_defective; (ii) absence of a blastp 
hit in the predicted proteomes of H. sapiens and C. lupus familiaris with an E-value below 10-
5; (iii) predicted function as an enzyme or receptor based on the annotation of the C. elegans 
ortholog and blastp searches against SwissProt). 
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Table 5. Potential drug targets of the heartworm endosymbiont, Wolbachia pipientis. As 
identified by the following exclusion criteria: (i) presence of orthologs in E. coli which are 
essential; (ii) absence of a blastp hit in the predicted proteomes of H. sapiens and C. lupus 
familiaris with an E-value below 10-5; (iii) predicted function as an enzyme or receptor based 
on the annotation of the E. coli ortholog and blastp searches against SwissProt. 
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Godel Christelle   29 ans 
Pré-Mermoud 2   Married, 1 child 
1580 Avenches   Swiss 
Phone +41 79 405 00 77 
Email csgodel@hotmail.com 
 
KEY COMPETENCES 
 
Ambitious, methodical, meticulous, implicated and consciencious in my job. 
 
FORMATION 
 
PhD ès Science in Parasite Molecular Biology     2009-2012 
PhD carried out at the Swiss Tropical and Parasitical Health, Basel, with a fellowship and 
project from Novartis Animal Health, St-Aubin FR.  
“Identification and characterization of potential AAD receptors in Dirofilaria immitis”” 
Side-project developed at the Ecole Polytechnique Fédérale de Lausanne (EPFL), ausanne, 
Development of an in vitro screening test in liquid culture involving the worm C. elegans.  
 
Master ès Science in Parasites Biology      2006-2008 
University Studies in Parasites Biology carried out at the University of Neuchâtel 
Master Thesis performed at Novartis Animal Health, St-Aubin FR :  
“Development of an in vitro test with model parasite of gerbils, Acanthocheilonema viteae, 
and target parasite, Dirofilaria immitis, affecting dogs”. 
 Optional courses in “Pharmaceutical Law and foods” and “Law and Medical Progress” 
 
Bachelor ès Science in Biology       2003-2006 
University Studies in Biology carried out at the University of Neuchâtel 
 
Veterinary Studies         2002-2003 
Universität Zurich, first year 
 
PROFESSIONAL EXPERIENCES 
 
Laboratory technician        2009 
Temporary post in the “Rodent Model” team , Dr. Sandra Schorderet-Weber, Novartis Animal 
Health SA, St-Aubin FR 
 In vivo tests following on Gerbils (Meriones unguiculatus), Rabbits and Mice; 
dissections, blood takings 
 Data treatment and results analysis 
 
Pratical Training in Molecular Biology      2008 
Laboratory of Dr. Alessandro Puoti, University of Fribourg 
 Use of molecular methods applicated to the nematode Caenorhabditis elegans, DNA 
extraction, RNA extraction, PCR, RT-PCR, Electrophoresis,… 
 Splicing assays, Backcrosses,… 
 
Module I of Animal Experimentation      2008 
“LTK Modul I: Einführung in die Labortierkunde”, Institut für Labortierkunde, Universität 
Zürich 
 
Master Thesis in Parasite Biology       2007-2008 
Screening laboratory, Dr. Jacques Bouvier, Novartis Animal Health SA, St-Aubin FR 
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 Development of in vitro tests with filarial nematodes, Acanthocheilonema viteae 
(microfilariae and L3) and Dirofilaria immitis (microfilariae). 
 Use of molecular methods applicated to filariae, A. viteae and D. immitis, RNA 
extraction, DNA extraction, PCR, RT-PCR, Electrophoresis,… 
 
Practical Training in Parasitology       2007 
Screening laboratory, Dr. Jacques Bouvier, Novartis Animal Health SA, St-Aubin FR 
 Development of in vitro tests with the nematode Trichostrongylus colubriformis (L3 
and L5) 
 
Student Assistant in Parasitology       2007 
Laboratory of Molecular Parasitology, Prof. Bruno Betschart, University of Neuchâtel 
 
Student Assistant in Eco-Ethology      2006-2007 
Laboratory of Eco-Ethology, Prof. Redouan Bshary, University of Neuchâtel 
 
Practical Training in Eco-Ethology       2006 
Laboratory of Eco-Ethology, Dr. Peter Neuhaus, University of Neuchâtel 
 Ethologic study of American Bisons, Elk Island National Park, Alberta, Canada 
 
SYMPOSIUMS, CONFERENCES 
 
SSTMP 
“Annual meeting for PhD student in Parasitology”, Münchenwiller, Prof. H.-P. Beck 
2008 
 
Swiss Tissue Culture Society 
“Nanoparticles-Biomedical Applications and Challenges”, Basel, Prof. P. Mäser 2009 
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“High-Definition Genomics-From Genome to Gene Function“, Zurich, Dr. L. Roggo 
           2009 
 
SSTMP 
“Annual meeting for PhD student in Parasitology”, Basel, Prof. H.-P. Beck  2009 
 
SSTMP 
“Diagnostics: From rapid tests to molecular diagnostics”, Basel, Prof. C. Lengeler  
           2009 
 
American Heartworm Society 
American Heartworm Society’s 13th Triennial Symposium, Memphis (USA), Lisa S. Scott 
           2010 
 
3e Cycle Symposium 
“Phylogenomics: New Perpectives for Phylogenetic Studies”, Geneva, Dr. J. Pawlowski 
           2010 
 
Interuniversity Doctoral Program in Organismal Biology (Ecology and Evolution) 
“Avoiding Tragedies of the Commons: An evolutionary Approach to Human Cooperation”, 
Neuchâtel, Dr. Christiane Bobillier       2010 
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De Novo Genome Assembly Workshop 
University of Lausanne, Dr. Laurent Falquet      2011 
 
WAAVP 
23rd International Conferenceof the World Association for the Advancement of Veterinary 
Parasitology 
Dr. G. Mauricio Bulman, Buenos Aires, Argentina     2011 
 
Symposium on Membrane Ion-channels in Helminth Parasite, Resistance and Sites of 
Action for Anthelmintics 
Presentation on the genome of the heartworm Dirofilaria immitis.  
Dr. R. Martin and Dr. A. Wolhstenholme, Philadelphia, USA   2011 
 
COURSES 
 
Course of Anesthesiology, Isabelle Iff, Novartis Animal Health Research Center,  St-Aubin 
FR           2012 
 
Data Management and Data Integrity, Compliance and Ethics training (v12) 
Novartis Animal Health Research Center, St-Aubin FR    2011 
 
Introduction to GLP (OCDE), Laboratory and Preclinical QA   2011 
 
Raw Data, Metadata and Processed Data in GLP Environment 
Laboratory and Preclinical QA, Advance Quality Program    2011 
 
LANGUAGES 
 
French  Mother tongue 
English First Certificate of English, University of Cambridge ESOL examinations 
  3 months of intensive language course, Calgary, Alberta, Canada 
German Intermediate, B1 (european standard of languages) 
  2 months of intensive language course, Regensburg, Germany 
Spanish Elementary, A2 (european standard of languages) 
 
PARALLELE ACTIVITIES  
 
Member of the SSTMP        2009 
(Swiss Society of Tropical and Medical Parasitology) 
 
Institut Council         2006-2008 
Representant of the University Master of Science, option Parasites Biology at the Biology 
Institut Council of the University of Neuchâtel 
 
INTERESTS 
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SSI and CMAS diving diploma, Youth diploma of rescue, J&S “Sport de camp/Trekking” 1 
and 2, Chef of scout group, Athletism instructor, Youth formation and animation, Course of 
first aid technician, Equestrian diploma 
 
Sports 
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Running, Horse riding, Cycling, Skiing, Snowboarding, Tennis playing 
 
Passions 
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Informatic  
 
JOBS IN PARALLELE TO STUDIES 
 
English Teaching Replacement, Secondary school of Avenches, Vaud  2011-2012 
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Work as Equestrian, Rafour stable, Montmollin     2006-2007 
 
Housework, for Private people       2007 
 
Maintenance and Cleaning work, Public Maintenance of the town of Neuchâtel (summer)
           2003-2007 
 
Housework in an elder house, Le Chalet, Bevaix     2002-2003 
 
Secretary, Zurich Insurance, Neuchâtel (summer)     2002 
 
Scholar support, in science at ESRN, Peseux     1995-1998 
 
